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3. INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease with a 
prevalence of 0.5–2%. The disease is characterized by an autoimmune process 
starting in the preclinical stage and resulting in damage to synovium- containing 
joints. Despite its predominant articular involvement, RA is a systemic disease 
with a wide variety of extra-articular features and comorbidities.  
The treatment of RA has dramatically evolved over the past decades (Smolen 
et al., 2017). RA treatment is currently targeted to remission induction through a 
threat to target strategy – an aim that was unreachable before (Smolen et al., 
2016). Though advances in the treatment of joint disease have improved the 
quality of life of patients with RA, non-articular features still contribute to the 
physical disability, psychological morbidity and premature mortality of RA 
(Cutolo et al., 2014; Giles, 2019).  
Although joint inflammation and destruction are responsible for disability and 
loss of quality of life, the main cause of excess mortality in RA is cardiovascular 
disease (CVD), accounting for nearly half of all the deaths, and being an 
important contributor to a mortality gap between patients with RA and the general 
population not entirely explained by traditional cardiovascular risk factors such 
as obesity or inflammatory activity (Agca et al., 2017; Cutolo et al., 2014; Giles, 
2019; Sokka, T. et al., 2008; Summers et al., 2010).  
The importance of cardiometabolic risk factors and alterations in body 
composition in the initial stage of RA is seldom the focus of research, so our 
study was undertaken to determine the important connections between these 
factors and changes. 
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4. LITERATURE REVIEW 
4.1. Early rheumatoid arthritis 
The first stage of the development of RA is the acquisition of genetic risk factors 
for the disease at conception, followed by gene-environmental interactions later 
in life. Smoking, respiratory mucosal inflammation, periodontitis and an altered 
gut microbiome are among the environmental factors potentially triggering 
autoimmune response (Tracy et al., 2017). 
A prolonged state of autoimmunity precedes the clinical onset of RA. The devel-
opment of seropositivity-production of autoantibodies targeted against citrullinated 
proteins (ACPA) and Fc portion of IgG (rheumatoid factor- RF) and T-cell 
infiltration with an increased expression of pro-inflammatory cytokines and 
chemokines has been demonstrated in this preclinical stage, years before symptoms 
of synovitis (Bijlsma et al., 2015; Tracy et al., 2017). Ultrasound and magnetic 
resonance imaging can visualize synovitis in clinically normal joints of patients 
later developing RA (Bijlsma et al., 2015). 
The concept of a “window of opportunity” refers to a period of weeks to months 
early in the course of the disease when the disease process can be altered or 
possibly even reversed. Currently, a symptom duration of up to 12–24 months is 
considered early, but the real duration of “the window of opportunity” is unclear, 
as significant damage can appear even in the first weeks to months after the onset 
of symptoms. The prognosis of early arthritis is often difficult to predict (Bijlsma 
et al., 2015), and a combination of clinical, laboratory and radiographic parameters 
have to be taken account to predict the outcome, although classification criteria 
for RA aid in diagnosing the disease earlier (Aletaha et al., 2010). 
Regularly updated and widely accepted treatment recommendations have been 
developed in consensus between European League against Rheumatism (EULAR) 
and the American College of Rheumatology (ACR) to reach optimal treatment 
outcomes, aiming to start disease modifying treatment before the onset of erosion 
in order to reduce, or even prevent, the risk of further joint damage and disability 
(Bijlsma et al., 2015; Combe et al., 2017) (Smolen et al., 2016, 2017). 
According to current recommendations on the management of early arthritis, 
disease-modifying anti-rheumatic drugs (DMARDs) should be ideally started 
within 3 months of the onset of the first symptoms (Combe et al., 2017). Prescribing 
DMARDs for early chronic inflammatory arthritis, preferably before the onset of 
erosion, can reduce or even prevent the risk of (further) joint damage and disability 
(Bijlsma et al., 2015; Combe et al., 2017).  
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4.2. Non-articular features of rheumatoid arthritis 
The incidence and severity of several non-articular manifestations, such as 
rheumatoid vasculitis and amyloidosis, has declined, but this does not seem to be 
shared by all RA comorbidities, such as accelerated atherosclerosis, interstitial 
lung disease, and sarcopenia that can already present in the pre-clinical or earliest 
stage of RA (Giles, 2019). Commonly used therapies, such as glucocorticoids 
(GCS) and non-steroidal anti-inflammatory drugs (NSAIDs), may themselves 
contribute to the development of dyslipidemia, hyperglycemia, atherosclerosis 
and osteoporosis. 
There is a lack of consensus how to define and classify the non-articular features 
of RA, and how to distinguish extra-articular manifestations form comorbidities 
(Giles, 2019; Prete et al., 2011). Classical extra-articular manifestations (vasculitis, 
Sjogren's syndrome, interstitial lung disease, and nodules) are directly driven by 
the cellular infiltration of activated immune effector cells into affected tissues, 
leading to structural damage and organ dysfunction (Giles, 2019). Comorbidities 
appear due to the effect of chronic inflammation – constitutional symptoms such 
as fatigue, infections, anemia, depression and other psychosocial manifestations 
are the ones seen most often. However, whether accelerated atherosclerosis, 
osteoporosis, and muscle loss are RA-associated comorbidities or extra-articular 
manifestations is still under discussion (Giles, 2019). 
 
 
4.3. Cardiovascular morbidity and mortality  
in rheumatoid arthritis 
A large prospective population-based cohort study of CVD end-points performed 
in England (12,120 individuals with RA and 121,191 comparators) found that RA 
patients had higher adjusted incidence rates of myocardial infarction (1.43), 
unheralded coronary death (1.60), heart failure (1.61) and cardiac arrest (2.26) 
(Pujades-Rodriguez et al., 2016). In addition, RA patients have more subclinical 
atherosclerosis and silent myocardial disease compared to the general population, 
which may not be accounted for during CVD risk evaluation (Błyszczuk & 
Szekanecz, 2020; Crowson et al., 2018). It has been suggested that the added risk 
for cardiovascular disease may precede the onset of synovitis (Maradit‐Kremers 
et al., 2005).  
There seems to be an important geographical heterogeneity in CVD risk in RA 
due to variations in both non-modifiable and modifiable characteristics of patient 
populations (Pappas et al., 2018). Looking into CORRONA registry data, the pre-
valence of traditional individual CVD risk factors (hypertension, smoking, hyper-
lipidemia, and hyperglycemia) and high disease activity was found to be higher 
in RA patients living in Eastern Europe and the finding was associated with CV 
risk more than twice that of subjects enrolled in USA, more than three times 
higher than in participants from Latin America, and more than seven times 
higher than in Indian participants (Pappas et al., 2018). 
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RA has been found to increase cardiovascular (CV) risk independently of 
traditional risk factors (age, male gender, smoking, history of CV disease, family 
history, diabetes, and hypercholesterolemia), with a RR of about 1.5 suggesting 
that different pathogenic mechanisms are responsible for the progression of 
cardiovascular disease among patients with RA. (Agca et al., 2017; Avina-Zubieta 
et al., 2012; Błyszczuk & Szekanecz, 2020; Hippisley-Cox et al., 2008; Piepoli et 
al., 2016; Yoshida et al., 2019). There seems to be a complex and often bidirec-
tional interaction between traditional and RA related risk factors, contributing to 
an increased CV risk (del Rincón et al., 2015; England, Thiele, et al., 2018). In 
2017, Crowson estimated that traditional CVD risk factors explain 49% of the 
risk and disease specific characteristics add 30% with a combined value of 70% 
in CVD risk prediction in established RA (Crowson et al., 2018). 
RA patients have an increased rate of traditional risk factors, but their relative 
contribution to CVD risk seems less in patients with RA than in the general 
population (Błyszczuk & Szekanecz, 2020; Boyer et al., 2011; Solomon et al., 
2003; Yu et al., 2018). Systemic inflammation through direct effect on the vessel 
wall and via modulation of traditional risk factors seems to have a pivotal role in 
the excess risk (Błyszczuk & Szekanecz, 2020; Nurmohamed et al., 2015; Piepoli 
et al., 2016; Skeoch & Bruce, 2015). 
CVD risk has been reported to increase even in the first year following RA 
onset (England, Thiele, et al., 2018; Mantel et al., 2015). Circulating inflammatory 
mediators may affect arterial walls, promoting the development of atherosclerosis 
due to enhanced endothelial dysfunction, plaque formation, destabilization and 
rupture. Atherosclerosis develops as a diffuse, systemic process and is already 
present many years before the first clinical manifestations occur, being more 
prevalent in RA than in general population (Skeoch & Bruce, 2015; van Sijl et 
al., 2011). There is evidence of the accelerated atherogenic process already taking 
place in the preclinical stage of RA but a lack of data from large-scale prospective 
studies (Bartoloni et al., 2010; Hannawi et al., 2007; Kerola et al., 2012).  
Additionally, some of the medications used in the treatment of RA – particu-
larly non-steroidal anti-inflammatory drugs and corticosteroids, are associated 
with higher CV morbidity (Agca et al., 2017; Błyszczuk & Szekanecz, 2020). 
Genetic predisposition could also be important – it has been hypothesized that the 
two conditions share genetic susceptibility factors but investigations in this area 
are still in their early stages (Skeoch & Bruce, 2015). CVD risk factors and RA 
characteristics explain about 70% of the risk for CVD outcomes, leaving 30% 
unaccounted for (Crowson et al., 2018). 
Widely used validated CV risk calculators for the general population tend to 
underestimate the added risk and are of limited value in RA. There are currently 
no disease-specific prediction models with proven accuracy available. Even RA-
specific CV risk scores have failed to be superior to general risk evaluation tools 
(Agca et al., 2017; Crowson et al., 2017; Hippisley-Cox et al., 2008; Piepoli et al., 
2016). Risk estimations from CV risk algorithms have found to deviate from 
observed risk, even in patients with early RA (Arts et al., 2015). The latest EULAR 
guidelines for CV risk management suggest using a multiplication factor of 1.5 
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for all patients with RA when using CV risk calculators created for the general 
population (Agca et al., 2017). It is possible that this approach might overestimate 
CV risk in some RA patients, but might underestimate it in other RA subgroups 
(seropositive, highly active disease) (Hollan et al., 2019). 
RA is traditionally believed to confer a 40–50% higher risk of mortality, a risk 
increase present even in the disease’s early stage (Abhishek et al., 2018; England, 
Thiele, et al., 2018; Kerola et al., 2012). A recent study evaluated the mortality rate 
in 5 years after an RA diagnosis from 1990 to 2009 compared to the general 
population and found that subjects diagnosed in 2007–2009 had a 15% excess 
mortality risk that is significantly lower than the 32–46% mortality risk found in 
cases incidental to earlier years (Abhishek et al., 2018). 
There is a trend towards decreasing CV mortality in incidental cases of RA. 
The RA death rate has declined in patients diagnosed and treated early with tight 
control of the inflammatory process according to current standards (Abhishek et 
al., 2018; Holmqvist et al., 2018; Kerola et al., 2015; Lacaille et al., 2017; Meek 
et al., 2014; Myasoedova et al., 2017). In a study by Myasoedova et al., a 58% 
decline in CV mortality and 83% decline in coronary heart related mortality in 
patients with RA onset in 2000–07 vs. 1990–99 was reported in men and women 
(adjusted for CV risk factors, age and seropositivity) (Myasoedova et al., 2017). 
At the same time, the mortality outcome of patients with established RA has 
remained unchanged (van den Hoek et al., 2016) and the gap in mortality in RA 
compared with the general population is still apparent (Holmqvist et al., 2018). 
There is a possibility that the effect on mortality appears due to the improved 
recognition and management of CV risk in RA patients – especially those with 
the highest degree of risk (Agca et al., 2017). The awareness of excess CVD risk 
in inflammatory disease has grown in recent years and peaked with EULAR 
recommendations for cardiovascular disease risk management in patients with 
RA (Agca et al., 2017; Peters et al., 2010). It is still too early to generalize stating 
that CV mortality in RA is declining, as data from large population-based cohorts 
of patients with RA with long-term follow-up is missing, and there is no 
information available on the time trends of subclinical atherosclerosis. 
 
 
4.4. Differences in cardiometabolic risk profile between 
general population and patients with rheumatoid arthritis 
4.4.1. Hypertension 
Hypertension affects about 1 billion people worldwide, and has one of the strongest 
associations with cardiovascular disease in general population (Panoulas et al., 
2008). There are several factors playing a role in the development of hypertension 
in RA. Chronic inflammatory status, genetic factors, low physical activity, smoking 
and the use of anti-inflammatory analgesics and glucocorticosteroids may syn-
ergistically lead to hypertension in patients with RA (Panoulas et al., 2008; Peters 
et al., 2010). The reported prevalence of hypertension in RA has been widely 
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variable in different studies, ranging from 4% to 73% (Boyer et al., 2011; Nurmo-
hamed et al., 2015). Several studies have demonstrated that the elevated blood 
pressure associated with subclinical atherosclerosis is one of the most significant 
independent predictors of CVD in RA (relative risk for CVD from 1.49 to 4.3) 
(Boyer et al., 2011; Crowson et al., 2018; Panoulas et al., 2008). Interestingly, in a 
meta-analysis published in 2011, no difference was found in the prevalence of 
hypertension between RA patients and the general population (Boyer et al., 2011). 
At the same time, it is known that hypertension among patients with RA might 
be underdiagnosed and suboptimally treated (Crowson et al., 2017; Ikdahl et al., 
2019; Nurmohamed et al., 2015; Pappas et al., 2018). The reported prevalence of 
treated hypertension has found to be widely variable, with rates ranging from 
21% to 80% of RA patients with elevated blood pressure using antihypertensive 
treatment in different studies (Panoulas et al., 2008; Pappas et al., 2018). 
 
 
4.4.2. Dyslipidemia  
Dyslipidemia leading to atherosclerotic plaque development, and characterized 
by high total and low-density lipoprotein (LDL) cholesterol, hypertriglyceridemia 
and low high-density lipoprotein (HDL), is an established predictor of CVD in 
the general population (Liao & Solomon, 2013). 
The prevalence of hyperlipidemia does not seem to be higher in RA patients 
compared to the general population, but chronic active inflammation is associated 
with hypertriglyceridemia and low HDL levels. This unfavorable atherogenic 
profile has been found in the preclinical state of RA (Boyer et al., 2011; Liao & 
Solomon, 2013; Peters et al., 2010) and even 10 years before the onset of the 
disease in donors later diagnosed with RA, in one study (Halm et al., 2007). It is 
not known whether the change in lipids is associated with the development of RA 
through a common socioeconomic (lifestyle) or genetic background. 
Active inflammation could impair the antioxidant action of HDL, decreasing 
its protective capacity further and leading to accelerated atherogenesis (Kerekes 
et al., 2014). Some conventional (hydroxychloroquine) and biological disease 
modifying drugs have been shown to correct impairments in the triglyceride/HDL 
ratio and thus have a potential for stabilizing the atherogenic profile (Bissell et 
al., 2016; Peters et al., 2010). 
Complicating matters is the fact that the low levels of total and LDL cholesterol 
often seen in active RA (and reported even before the onset of RA) have been 
linked to an increased risk of CVD – a phenomenon called the lipid paradox, with 
a U-shaped relationship between cholesterol quantity and cardiovascular morbidity 
(Crowson et al., 2018; England, Thiele, et al., 2018; Hollan et al., 2019; Kerekes 
et al., 2014; Liao & Solomon, 2013; Myasoedova et al., 2010). Taking this into 
account, statin therapy may not decrease CV risk in RA in a level seen in the 
general population. 
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4.4.3. Adiposity  
Obesity is a recognized risk factor for CVD in the general population. Optimal 
survival is achieved at a body mass index (BMI) of 22.5–25 kg/m2 with reductions 
in life expectancy of 3 and 10 years in individuals with moderate and extreme 
obesity, respectively (Huxley et al., 2010; Prospective Studies Collaboration, 
2009). The prevalence of obesity has increased two- to three-fold over the last 
30 years (Timmis et al., 2019). In 2016, 39% of the world’s adult population was 
overweight according to World Health Organization (WHO) data (WHO, 2020). 
Previous research has shown that in Estonia, 29% of men and 34% of women are 
classified as obese (Eglit et al., 2013). 
Adipose tissue is the main energy storage unit of the body, and additionally 
serves to produce adipokines, a type of bioactive hormone (Laakso, 2015; Van 
de Voorde et al., 2013). Adipokines are the main mediators in interaction between 
adipose tissue, the heart and vasculature. Aberrant production of these mediators 
could be the key link between obesity and elevated CV risk – either directly leading 
to endothelial dysfunction and atherosclerosis, or through inducing insulin 
resistance, type 2 diabetes, hypercoagulation, hyperlipidemia and hypertension 
(Patel et al., 2016; Van de Voorde et al., 2013). 
Individuals with similar BMI can have different CV risks due to differences in 
body fat distribution, as adipose tissue located in different areas can vary in 
adipokine production profiles (Van de Voorde et al., 2013). Measures of visceral 
adiposity have been suggested to be superior to BMI in predicting CV risk (Huxley 
et al., 2010; C. M. Y. Lee et al., 2008). Visceral fat is probably the type presenting 
with the most pro-atherogenic profile through adipose tissue inflammation, leading 
to a range of metabolic abnormalities, including decreased glucose tolerance, 
insulin resistance and dyslipidemia – risk factors for type 2 diabetes and CVD 
(Antonopoulos & Tousoulis, 2017; Huxley et al., 2010). At the same time, fat 
accumulation in the hips and thighs has little or no effect on CV risk. The different 
patterns of fat distribution explain the gender (“apple type”– fat distribution with 
excess visceral fat in men and “pear type” in women) specific differences in CV 
mortality and also hint at what lies behind geographical differences in CV risk 
profiles – for example, Asians have higher CV risk profiles with elevated visceral 
fat mass, even when not overweight (Van de Voorde et al., 2013). 
The question of whether individuals with RA have a higher BMI and 
prevalence of overweight and obesity compared with the general population is 
controversial (Liao & Solomon, 2013). There is some evidence of modest 
associations between obesity and the development of RA (George & Baker, 2016) 
and lower response rates in obese patients treated with both biologic and non-
biologic therapy, even after adjustments for age, sex, smoking, and seropositivity 
(George & Baker, 2016; Heimans et al., 2013; Sandberg et al., 2014). No clear 
evidence behind the mechanism of the association between obesity, incidence of 
RA, and poor response to therapy has been established (George & Baker, 2016). 
Some studies have shown a higher prevalence of RA in obese subjects (Ljung 
& Rantapää-Dahlqvist, 2016; Pedersen et al., 2006; Symmons et al., 1997; Voigt 
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et al., 1994), while others have reported the opposite (Cerhan et al., 2002; George 
& Baker, 2016; Hernández Avila et al., 1990; Liao & Solomon, 2013; Rodríguez 
et al., 2009; Turesson et al., 2016). In a meta-analysis, a relative risk of 1.31 (95% 
CI 1.12–1.53) for RA was found for obese subjects (Qin et al., 2015).  
In some studies, only an association between obesity and seronegative RA has 
been shown (Lahiri et al., 2014; Pedersen et al., 2006). Obesity has been 
associated with elevated C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR) values related to fat mass and not RA disease activity (George et al., 
2017), and also higher patient-reported outcomes, including increased pain, fatigue 
and lower quality of life scores (but not swollen joint counts) independent of 
disease activity (Katz, 2017; Levitsky et al., 2017; Liu et al., 2017). It can be 
hypothesized that it is likely that some patients in these studies have been mis-
classified and do not actually have inflammatory arthritis, as radiographic studies 
have demonstrated a lower risk of joint damage in obese patients despite a 
clinically poor response to therapy (Baker et al., 2011; George et al., 2017).  
When looking into the data on the body composition of RA patients, it is evident 
that they have more body fat for a given BMI than healthy controls – frequently 
presenting as abdominal obesity with excess visceral fat (Giles et al., 2010; 
Kerekes et al., 2014; Liao & Solomon, 2013). While obese individuals with RA 
are commonly seronegative, with less erosive disease, abnormal body fat distri-
bution is associated with higher disease activity and more severe RA (Giles et al., 
2010; Liao & Solomon, 2013). Excess visceral fat could be an important con-
tributor to CV risk elevation in patients with RA.  
Obesity has been associated with decreased CVD mortality in patients with 
established RA (England et al., 2016; Escalante A et al., 2005; George & Baker, 
2016; Wolfe & Michaud, 2012) but data on early arthritis are lacking (Kerekes et 
al., 2014). 
 
 
4.4.4. Hyperglycemia  
Hyperglycemia and type 2 diabetes have been reported to be precursors to CV 
disease. In diabetic patients, 65% of deaths are found to be associated with CVD 
(Patel et al., 2016). The global prevalence of diabetes has nearly doubled since 
1980, growing to 8.5% in the adult population in 2016 (Roglic & World Health 
Organization, 2016). Using aggressive therapy for diabetes, the risk of CVD is 
reduced by only about 42% – possibly due to the occurrence of systemic insulin 
resistance, leading to micro and macrovascular complications (Patel et al., 2016). 
In most of the studies looking into the presence of diabetes in RA, an 
association between the two conditions has been found (Nicolau et al., 2017). In 
a meta-analysis, the odds of diabetes in RA was 1.74 (95% CI 1.22, 2.50) times 
higher than in the general population (Boyer et al., 2011). Interestingly in a large 
study looking into data in a UK general population database, the hazard ratio for 
diabetes in RA was 1.12 (95% CI 1.01, 1.25), but after adjustment to BMI, 
smoking, alcohol, glucocorticoid usage, and co-morbidities, the added risk 
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disappeared (HR 0.94 (95% CI 0.84, 1.06)) (Dubreuil et al., 2014) suggesting 
lifestyle factors play a role in the development of diabetes (Nicolau et al., 2017). 
 
 
4.4.5. Low physical activity  
Lack of exercise is an emerging pandemic associated with 5.3 million deaths per 
year through many adverse health conditions (I.-M. Lee et al., 2012). In a large 
meta-analysis, physical activity was associated with a risk reduction for CVD of 
35% in the general population (Nocon et al., 2008). Exercise has a beneficial 
effect on body weight and visceral adipose tissue (Verheggen et al., 2016), cho-
lesterol levels (Mann et al., 2014), blood pressure (Cornelissen & Smart, 2013) 
and glucose metabolism (Boulé et al., 2001). 
Patients with RA are less physically active compared with healthy controls 
(Hernández-Hernández et al., 2014; Sokka T. et al., 2008; Verhoeven et al., 2016) 
due to the pain and loss of function caused by active inflammation, joint damage 
or fear of potential harm. It has been found that a low level of physical activity 
before the onset of RA is associated with a higher disease burden, some studies 
even suggest that physical activity can protect against the development of RA 
(Verhoeven et al., 2016). Exercise has a potential benefit in reducing the burden 
of atherosclerosis in RA (Metsios et al., 2019; Verhoeven et al., 2016), and is 
promoted as an integral part of standard care for chronic inflammatory arthritis 
in the 2018 EULAR recommendations for physical activity (Osthoff et al., 2018). 
 
 
4.4.6. Smoking  
Smoking is one of the most important cardiovascular risk factors, and also one of 
the most established risk factors for the development of RA, due to gene-
environment interaction via the induction of citrullination in the lungs of patients 
carrying the shared epitope of HLA-DRB1 (Hedström et al., 2018). Smoking 
increases the risk of not only ACPA positive (OR 1.9, 95% CI 1.7, 2.1), but also 
ACPA negative, RA (OR 1.3, 95% CI 1.2, 1.5). The risk of development of ACPA 
positive RA persists even 20 years after the cessation of smoking (Hedström et 
al., 2018). 
Current and former smoking is associated with an increased risk for the 
development of cardiovascular disease in patients with RA, with a higher risk in 
men than women (Agca et al., 2017; Crowson et al., 2018; Kerola et al., 2012).  
 
 
4.4.7. Metabolic syndrome 
Metabolic syndrome (MetS), the clustering of metabolic disturbances like hyper-
tension, hyperglycemia, and gout, was first described in the 1920 by the Swedish 
physician Eskil Kylin (R. H. Eckel et al., 2005). The concept of metabolic 
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syndrome was later established by Gerald Reaven in 1988, under the name of 
“Syndrome X,” which referred to co-occurring impaired glucose metabolism, 
insulin resistance, central obesity, dyslipidemia, and hypertension, leading to a 
higher CV risk than the sum of its individual components (R. H. Eckel et al., 
2005; Isomaa et al., 2001).  
 
 
Metabolic syndrome in general population 
Over the recent decades, a striking increase in the prevalence of MetS has 
appeared, largely due to the worldwide obesity epidemic. Currently around 25% 
of the world’s population has been reported to have metabolic syndrome (Ferraz-
Amaro et al., 2013; Saklayen, 2018). In Estonia, the prevalence of MetS has been 
reported to be 28% (95% C.I 24.0, 32.1), a bit higher in men (30%) and somewhat 
lower in women (25%) (Eglit et al., 2012). 
MetS has been shown to be a strong predictor of diabetes, cardiovascular disease 
and increased risk of (age, smoking and cholesterol adjusted) mortality in several 
prospective studies and meta-analyses (R. H. Eckel et al., 2005; Galassi et al., 
2006). The presence of MetS is associated with a twofold increase in cardiovascular 
outcomes (CVD, CVD mortality, stroke and myocardial infarction) and a 1.5-fold 
increase in all-cause mortality among the general population (Mottillo et al., 2010). 
There are several definitions for metabolic syndrome (National Cholesterol 
Education Program Adult Treatment Panel III – NCEP-ATP III 2001, 2004; World 
Health Organization, International Diabetes Federation, and European group for 
the Study of Insulin Resistance), but they have proven to be of similar accuracy 
in cardiovascular risk assessment (Ferraz-Amaro et al., 2013). According to the 
easiest to implement and most widely used criteria, the NCEP-ATP III, metabolic 
syndrome is defined by the presence of hyperglycemia (fasting plasma glucose 
levels ≥5.6 mmol/l), central obesity (waist circumference ≥90 cm in men, and 
≥80 cm in women), low HDL levels (<1.03 mmol/l in men, <1.29 mmol/l in 
women), high total triglyceride (TG) levels (≥1.7 mmol/l), and elevated blood 
pressure (≥130/85 mmHg) or taking antihypertensive drugs (“Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III) Final Report,” 2002). 
The only study found evaluating the performance of different criteria for MetS 
in cardiovascular risk prediction in RA, reported that the WHO criteria were 
superior to the NCEP-ATP III definition in predicting increased intima-media 
thickness (Dessein et al., 2006). The WHO criteria differ from the NCEP-ATP 
III criteria by mandating the presence of insulin resistance, taking into account 
total obesity instead of central obesity and adding the presence of microalbu-
minuria to the model (Alberti & Zimmet, 1998). As insulin resistance is a pre-
requisite for diagnosing MetS according to the WHO criteria, it is unclear if the 
added risk can be attributed to insulin resistance and how much MetS adds as a 
complete syndrome. 
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Metabolic syndrome in RA 
There have been several studies investigating the presence of MetS in RA. An 
association has been confirmed between subclinical atherosclerosis and MetS in 
RA (Burggraaf et al., 2018), but the evidence is not uniform, and prevalence rates 
have been quite variable due to geographical heterogeneity and the differing 
criteria used in the estimation of MetS. 
Several previous studies, including two meta-analyses, show a significantly 
higher prevalence of MetS in established RA compared to control subjects (OR 
1.4–1.9) (Abourazzak et al., 2014; Burggraaf et al., 2018; Chung et al., 2008; 
Crowson et al., 2011; da Cunha et al., 2012; Hallajzadeh et al., 2017; Kerekes et 
al., 2014; Zhang et al., 2013), with a pooled prevalence of 31% (95% CI: 27.87–
33.43) (Hallajzadeh et al., 2017). Some other researchers have reached the 
opposite conclusion, reporting a higher prevalence of MetS in the healthy controls 
(Karimi et al., 2011; Mok et al., 2011; Sahebari et al., 2011; Šalamon et al., 2015). 
There seems to be a difference in the prevalence of MetS among patients with 
early rheumatoid arthritis (ERA) and those with long-standing disease, although 
no prospective studies have confirmed an increased risk of MetS development 
during the course of RA (Kerekes et al., 2014).  
The estimated prevalence of MetS in the early stage of the disease has ranged 
from 16% to 31% in different studies (Kerekes et al., 2014; Kuriya et al., 2019). 
Recently, an observational study using data from the Canadian Early Arthritis 
Cohort (CATCH) classified 31% of 1543 ERA subjects as having MetS, according 
to a modified definition based on routinely collected clinical data (Kuriya et al., 
2019).  
The metabolic profile observed in patients with RA seems to be different from 
the MetS mostly associated with obesity in the general population. RA patients 
tend to have a higher prevalence of abdominal adiposity, hypertension, and 
altered glucose metabolism, but there is a difference in lipid levels (the “lipid 
paradox”) and body composition in RA compared to non-inflammatory states. 
Paradoxically, overweight and obese RA patients appear to carry the lowest CV 
risk (Kerekes et al., 2014).  
A subtype called normal weight metabolically obese – normal-weight indi-
viduals with metabolic disturbances (hypertension, hyperglycemia, dyslipidemia) 
that are characteristic of obesity – has been recognized in the general population 
and could be even more prevalent in those with RA (Chung et al., 2008; Mathew 
et al., 2016; St-Onge et al., 2004). 
 
 
4.4.8. Insulin resistance 
Insulin plays a central role in carbohydrate and lipid metabolism (Patel et al., 
2016). Early stage glucose intolerance may be compensated for by increased 
insulin secretion. Insulin resistance (IR) is the term used to describe the inability 
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of insulin to regulate glucose metabolism due to an inadequate response in peri-
pheral target tissues such as skeletal muscle, adipose tissue, and liver (American 
Diabetes Association, 2014; Laakso, 2015). IR is not only a matter of deficient 
glucose uptake, but also a major determinant of CVD risk in nondiabetic indi-
viduals (Laakso, 2015). 
IR is a long-established predictor of atherosclerosis and coronary artery disease, 
independent of other risk factors (Després et al., 1996; Patel et al., 2016; Pyöräla, 
1979). Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) is a 
simple and widely used surrogate measure used to detect IR in investigational 
studies (Matthews et al., 1985). This is an alternative for the reference method for 
quantifying insulin sensitivity, the euglycemic-hyperinsulinemic glucose clamp 
method, which is complex and costly (Laakso, 2015). Different cut-off values have 
been suggested, but there is no universal definition for IR via HOMA-IR values. 
 
 
Insulin resistance in the general population 
A meta-analysis of 65 studies, with a total of 516,325 participants, demonstrated 
that IR measured by HOMA-IR is associated with a 1.6 times (95% C.I. 1.35, 
2.00) increase in the risk of cardiovascular disease in patients without diabetes 
(Gast et al., 2012). It has been even stated that IR is the most important single 
cause of coronary artery disease, and in young adults preventing IR could avoid 
42% of myocardial infarctions, based on a study using a simulated population 
representative of young adults in the USA National Health and Nutrition 
Examination Survey (NHANES) 1998–2004 data (Eddy et al., 2009). 
IR is tightly associated with obesity, as well as type 2 diabetes, hypertension, 
and lipid abnormalities (DeFronzo & Ferrannini, 1991; Nicolau et al., 2017), and 
plays a central role in the development of metabolic syndrome – one of the most 
important determinants in the development of CVD (Laakso, 2015; Mottillo 
et al., 2010; Nicolau et al., 2017).  
IR contributes to an enhanced rate of atherosclerosis and cardiovascular risk 
through multiple pathways, via changes in classic cardiovascular risk factors and 
downregulating insulin signaling pathways in skeletal muscle, adipose, and liver 
tissues (Laakso, 2015; Patel et al., 2016). IR in skeletal muscle causes post-prandial 
hyperglycemia, while in adipose tissue, it increases cytokine and adipokine 
production, and leads to low-grade inflammation and the development of systemic 
IR, which contributes to the increased transport of fatty acids to the liver, promoting 
dyslipidemia (Laakso, 2015). At the same time, over-activation of the sympathetic 
nervous system induced by IR leads to hypertension and obesity (Laakso, 2015; 
Patel et al., 2016). IR in endothelial cells leads to impaired vasodilatation and 
endothelial damage, and at the macrophage level, contributes to atherosclerotic 
plaque necrosis, instability and enhanced thrombogenesis (Laakso, 2015). 
It has been widely established that differences in weight modulate insulin 
action. Insulin sensitivity declines linearly with BMI, and about 25% of obese 
subjects in the general population have been reported to be insulin resistant (Abbasi 
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et al., 2002; Ferrannini et al., 1997). IR in the general population is associated 
primarily with increasing BMI levels. Adding dual-energy X-Ray absorptiometry 
(DXA) measured body fat percentage does not add much to the utility of BMI in 
the prediction of IR, according to NHANES data (Martinez et al., 2017). 
Adipose tissue accounts for only 10% of whole-body glucose disposal but has 
a major role in the development of IR. Hypertrophy of adipose cells leads to the 
infiltration of immune cells in visceral adipose tissue (but not in subcutaneous 
deposits) in response to adipocyte hypoxia or apoptosis. Large adipocytes are less 
sensitive to the anti-lipolytic action of insulin and express higher levels of the 
proinflammatory chemokines. Ectopic lipid accumulation in other tissues activates 
local inflammation and lipotoxicity, contributes to organ-specific disease, and 
exacerbates systemic IR (Laakso & Kuusisto, 2014).  
A higher proportion of visceral fat is one of the determinants of the higher risk 
of CVD induced by IR in men. In men, there is a bidirectional association between 
low levels of testosterone and central obesity mediated by adipokines through the 
hypothalamic–pituitary–gonadal axis (Geer & Shen, 2009; Rao et al., 2013).  
Additionally, changes in gut microbiota (dysbiosis) in obese subjects promoting 
systemic inflammation due to gastrointestinal permeability, and an increase in 
circulating bacterial lipopolysaccharides and DNA, can have a role in the devel-
opment of IR (Johnson & Olefsky, 2013). 
 
 
Insulin resistance in rheumatoid arthritis 
It is now established from a variety of studies that HOMA-IR levels in rheumatoid 
subjects are higher than those of population controls, regardless of stratification by 
demographic or cardiometabolic risk factors (Chung et al., 2008; Giles et al., 2015; 
Manrique-Arija et al., 2015; Montagna et al., 2007; Nicolau et al., 2017; Shahin 
et al., 2010). 
The prevalence of IR has been found to be 22% (Manrique-Arija et al., 2015) 
to 73% (Shahin et al., 2010) in early RA and up to 88% in subjects with established 
disease (Montagna et al., 2007). The presence of IR is associated with inflammatory 
activity – the level of increase of RA-elevated inflammatory markers (CRP, TNF-
alpha, IL-6), high clinical disease activity in both early and longstanding RA, and 
seropositivity (Gallagher et al., 2019; Giles et al., 2015; Guin et al., 2019; Nicolau 
et al., 2017; Pamuk et al., 2006).  
The fact that increased BMI in the general population leads to a higher risk of 
disturbed insulin sensitivity is well-known, but interestingly, Giles has reported 
the largest relative difference between HOMA-IR values in controls and RA 
patients in the normal weight group, suggesting the importance of other factors 
involved in the development of IR in RA (Giles et al., 2015). 
Glucocorticoids induce IR through the stimulation of hepatic neoglucogenesis, 
enhanced pancreatic release of insulin, and diminished peripheral insulin sensitivity 
(Nicolau et al., 2017). Previous research indicates that chronic glucocorticoid 
therapy is associated with a higher risk of IR (Dessein et al., 2004; Giles et al., 
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2015; Nicolau et al., 2017). EULAR recommends weaning patients off gluco-
corticoids as early as possible to avoid worsening IR and the eventual development 
of type 2 diabetes (Peters et al., 2010). On the other hand, it has been suggested 
that the suppression of systemic inflammation through short-term glucocorticoid 
use may overweigh the detrimental effects of glucocorticoids (Uyl et al., 2012). 
Overexpression of TNF-alpha plays a role in the pathophysiology of IR by 
disrupting the insulin signaling pathway, resulting in reduced insulin sensitivity, 
the stimulation of adipose tissue lipolysis, and diminished circulating levels of 
adiponectin (Nicolau et al., 2017). Anti TNF-alpha therapy has been shown to 
play a beneficial role in reducing IR in rats (Borst, 2004). Men tend to have an 
enhanced response to inflammatory stimuli through the overproduction of pro-
inflammatory cytokines (mainly TNF-alpha, IL-6 and IL-1b) that can decrease 
androgen production through negative feedback in the hypothalamic–pituitary–
gonadal axis and lead to a further risk of IR (Geer & Shen, 2009; Rao et al., 2013).  
Using intensive treatment strategies, including TNFalpha targeted treatment, 
can improve insulin sensitivity (Bissell et al., 2016; Burska et al., 2015; Corrado 
et al., 2019). A dramatic improvement of insulin and glucose levels has been 
demonstrated by assessing data prior to and after an intravenous infusion of 
Infliximab in RA (Gonzalez-Gay et al., 2006). Of the conventional DMARDs, 
hydroxychloroquine seems to have a beneficial effect on glucose metabolism, 
independent of inflammation control (Nicolau et al., 2017). 
There is a controversy regarding the role of IR in the RA-related CV risk 
elevation. Although the prevalence of IR is higher in RA patients than in non-RA 
controls, there is some doubt regarding the role of IR in the development of 
atherosclerosis in RA. There have been reports of significant association between 
IR and subclinical atherosclerosis (Guin et al., 2019; Montagna et al., 2007) in 
RA, but some other researchers have come to the conclusion that higher level of 
IR may not independently impart additional risk (Chung et al., 2008; Giles et al., 
2015; González-Gay et al., 2015). We could not find any long-term observational 
studies on the topic. 
 
 
4.4.9. Body composition  
Sarcopenia 
Loss of muscle mass and function is a natural part of aging. In 1989, Irwin 
Rosenberg proposed the term “sarcopenia” (Greek “sarx”– flesh+ “penia”– loss) 
to describe the decrease of muscle mass related to old age (Rosenberg, 1989). 
Sarcopenia was later defined as the loss of not only skeletal muscle mass, but also 
a decline in muscle strength and function (dynapenia), associated with a risk of 
adverse outcomes (Cruz-Jentoft et al., 2010, 2019; Marzetti et al., 2017).  
Primary sarcopenia is mainly associated with aging. Age-related sarcopenia is 
mediated through an altered diet, reduced physical activity worsened by a 
decreased anabolic response to feeding and exercise, and by chronic low-grade 
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inflammation with elevated cytokine IL-6 and TNF-alpha levels, a phenomenon 
known as “inflammaging” (Beaudart et al., 2017; Cruz-Jentoft et al., 2019; Dent 
et al., 2018; Wilson et al., 2017). The prevalence rates of sarcopenia in the elderly 
have ranged from 3% to 24%, depending on the diagnostic criteria used (Dent 
et al., 2018; Tournadre et al., 2018).  
Secondary sarcopenia can develop as a consequence of low physical activity, 
malnutrition, and diseases such as endocrine disorders, malignancy, chronic 
inflammatory conditions or advanced organ failure (Marzetti et al., 2017).  
Sarcopenia is associated with an increased risk of disability, impaired quality 
of life, higher frequency of falls, osteoporosis, dyslipidemia, cardiovascular risk, 
metabolic syndrome, immunosuppression and mortality (Cruz-Jentoft et al., 
2019; Marzetti et al., 2017).  
Dual-energy X-Ray Absorptiometry (DXA) is currently the most widely used 
method in BC evaluation, enabling a precise and stable quantification of BC, with 
minimal radiation, separating body lean, fat and bone mass (Marzetti et al., 2017; 
Shepherd et al., 2017).  
There is no universal definition of sarcopenia. Several criteria have been pro-
posed, based on the muscle quantity, muscle strength, and/or physical performance 
(muscle quality). Muscle quantity can be reported by appendicular lean mass 
(ALM)- the combined muscle mass of hands and legs. As muscle mass is 
correlated with body size (individuals with a larger body size have larger lean 
mass), when quantifying muscle mass, lean mass can be adjusted for body size 
using height squared (ALM/height2 ), weight (ALM/weight) or body mass index 
(ALM/BMI), with no clear advantage of any of the methods (Cruz-Jentoft et al., 
2019).  
 In 2019, the European Working Group on Sarcopenia in Older People 
(EWGSOP) proposed a scheme for the detection of sarcopenia, taking into 
account muscle quantity, muscle strength and performance (Cruz-Jentoft et al., 
2019). The implementation of these criteria has not been tested in subjects with 
RA. Measures of muscle strength and performance (e.g., grip strength) in patients 
with RA can be affected by various patient-related factors, such as pain, arthritis 
activity, deformities, and disability resulting in values lower than in healthy 
individuals, and representing burden of the disease more than muscle quality 
(Higgins et al., 2018; Uutela et al., 2018). On the other hand, using EWGSOP 
criteria can lead to an underestimation of sarcopenia in the general population. 
Avoiding this through diagnosing sarcopenia by appendicular lean mass adjusted 
to height value alone has been recently suggested (Dawson-Hughes & Bischoff-
Ferrari, 2016).  
 
 
Sarcopenic obesity and insulin resistance 
Sarcopenic obesity – the co-occurrence of obesity and sarcopenia – seems to be 
associated with higher risk for adverse effects than either of its components alone 
(Tournadre et al., 2018). Obesity exacerbates sarcopenia through the infiltration 
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of fat into muscle, reducing physical function and increasing the risk of mortality 
(Cruz-Jentoft et al., 2019). 
In sarcopenic obesity, lean mass loss is accompanied not only by a gain in 
visceral fat, but also fat infiltration in skeletal muscle (myosteatosis) with an 
accumulation of toxic lipids – ceramides and triglycerides (Hong & Choi, 2020; 
Kalyani et al., 2014; Tournadre et al., 2018).  
Skeletal muscle is the largest insulin-sensitive tissue, and has the highest 
glucose requirements, accounting for up to 80% of glucose uptake during hyper-
insulinemia (Laakso & Kuusisto, 2014). An inverse relationship between skeletal 
muscle mass and IR has been reported in the general population (Cleasby et al., 
2016; Srikanthan et al., 2010; Srikanthan & Karlamangla, 2011). In sarcopenic 
obesity, insulin-stimulated glucose disposal in skeletal muscle is markedly 
impaired, leading to catabolic status and skeletal muscle atrophy (Hong & Choi, 
2020). Sarcopenic obesity is associated with more severe functional decline and 
outcomes than either condition alone (Cleasby et al., 2016; Kalyani et al., 2014; 
Tournadre et al., 2018). 
 
 
Body composition in rheumatoid arthritis 
The phenomenon known as “rheumatoid cachexia” was first described by Sir 
James Paget, who wrote: “... wasting occurs, in greater or lesser degree, in all 
muscles near joints that are inflamed... It is, I repeat, not a mere wasting from 
disuse: it is far more rapid that that...” in the Lancet in 1873 (Paget, 1873). The 
term “cachexia” was defined in 2008 as “a complex metabolic syndrome 
associated with underlying illness and characterized by loss of muscle with or 
without loss of fat mass” (Evans et al., 2008). Nowadays, the prominent feature 
of classic cachexia – weight loss – is rare in RA, although it’s sometimes seen in 
severe longstanding untreated arthritis (Summers et al., 2010).  
While in sarcopenia related to aging, a parallel loss of fat mass appears and 
total body mass declines (Kalyani et al., 2014), sarcopenia in RA usually 
develops without a change in body mass (Summers et al., 2010). An abnormal 
body composition appears with loss of muscle and concomitant fat mass 
preservation or accumulation (Challal et al., 2015; Summers et al., 2010). Due to 
the change in body composition (BC) at the same BMI and weight, patients with 
RA have significantly lower lean mass compared to the healthy population, 
making this form of cachexia difficult to recognize by clinical examination alone. 
To date, there is no accepted operational definition for rheumatoid cachexia. 
Evidence of muscle wasting (sarcopenia) and fat mass gain (overfat) without 
a change in body weight, known as sarcopenic obesity or rheumatoid cachexia, 
has been reported in up to two thirds of RA patients with established disease 
(Challal et al., 2015; Rall & Roubenoff, 2004; Roubenoff, 2009; Roubenoff et al., 
1992; Summers et al., 2010). In a recent meta-analysis, the prevalence of 
rheumatoid cachexia was found to be 15–32% depending on the criteria used 
(Santo et al., 2018). 
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Contrary to the general population, an inverse relationship between BMI and 
risk of death in RA has been found, phenomenon known as the “obesity paradox.” 
Obesity in RA protects against cardiovascular mortality and weight loss is 
associated with elevated CV risk (Baker et al., 2015; England, Baker, et al., 
2018). To date, no studies have directly evaluated the role of altered BC in CV 
mortality in RA. Findings by Delgado Frias and his colleagues suggest that 
sarcopenia in RA is associated with endothelial dysfunction (reduced brachial 
artery flow-mediated dilatation), possibly leading to a higher cardiovascular risk 
(Delgado-Frías et al., 2015).  
 
 
Factors affecting body composition in rheumatoid arthritis 
In 1992, Roubenoff first reported that rheumatoid cachexia is associated with 
mediators of inflammation (Roubenoff et al., 1992). The loss of muscle tissue in 
RA seems to be mediated through pro-inflammatory sarcoactive cytokines, 
including TNF-alpha, IL-1, and IL-6, which induce proteolysis (Engvall et al., 
2008; Tournadre et al., 2018).  
The long-term effect of glucocorticosteroids – potent anti-inflammatory 
medications leading to muscle wasting, fat accumulation, and fat redistribution – 
is a well-known phenomenon (Buttgereit & Burmester, 2016; Cutolo et al., 2014). 
Interestingly, when using tightly controlled therapy (a treat-to-target approach) 
(Lemmey et al., 2016) or biological treatment, even if started early (S. M. 
Marcora et al., 2006; Marouen et al., 2017), disease activity decreases, but the 
loss of lean mass is resistant to change. TNF-alpha targeting therapy could lead 
to further worsening of BC due to a gain in fat mass (Tournadre et al., 2018). 
Regarding the effect of IL-6 inhibitors, in one study, a beneficial effect to lean 
mass was reported without a gain in fat tissue, possibly through an effect 
mediated by leptin modulation (Tournadre et al., 2017).  
Some authors have found unfavorable BC to already be evident in the initial 
stage of RA, potentially mediated by preclinical immunologic events (Giles, 
2019). There is no general agreement for which factors contribute to this change 
(Book et al., 2009, 2011; Dao et al., 2011; Giles, 2019; S. M. Marcora et al., 2006).  
A Swedish group reported that ERA patients with a mean disease duration of 
7 months had lower lean mass, but only women with RA were found to have a 
higher fat mass compared to controls. Lean mass reduction was associated with 
advanced age, but no association was found with disease specific measures (Book 
et al., 2009). After two years of routine care (including DMARD treatment and 
rehabilitation), the same researchers found that further decrease in lean mass and 
increase in truncal fat was lower in the RA group compared to control subjects, 
showing that the change could be potentially modifiable (Book et al., 2011).  
A higher prevalence of altered BC has been reported by a Vietnamese group 
focusing on women with RA (with a mean disease duration of 22 months) 
compared to matched controls. In this group, a change in BC was associated with 
RA activity and disability, and a lower frequency of regular exercise in sarcopenic 
27 
subjects. Additionally, the role of glucocorticoid usage (68% of the patients were 
taking GCS) was evaluated, but no associations were found with either fat nor 
lean mass measures (Dao et al., 2011). In neither of the groups studied were 
treatment naïve RA patients.  
BC in early arthritis patients with no previous DMARD treatment was 
evaluated in a study by Turk et al, which found that loss of muscle mass was 4–
5 times more common in patients with arthritis than controls, but no associations 
between disease activity and an unfavorable BC were found (Turk et al., 2018). 
In previous studies, the role of lifestyle in association with lean mass parameters 
has rarely been assessed. 
A healthy diet, especially with sufficient protein intake, is essential for the 
prevention of age-related loss of muscle mass, so protein supplementation is recom-
mended for treating age-related sarcopenia (Beaudart et al., 2017; Dent et al., 
2018; Geirsdottir et al., 2013; Tournadre et al., 2018). Sarcopenia in RA is believed 
to develop without changes in diet (Engvall et al., 2008; Rall & Roubenoff, 2004). 
It has been reported that up to 75% of RA patients believe food plays an important 
role in their symptom severity but the role of diet is less accepted by physicians in 
the management of RA (Cutolo & Nikiphorou, 2018; Stamp et al., 2005). Most 
researchers studying BC change in RA have not looked very closely into nutrition. 
The role of protein supplementation (a mixture of β-hydroxy-β-methyl-
butyrate, glutamine and arginine) has been evaluated in established rheumatoid 
cachexia but found to be no different than placebo in a short term interventional 
study (S. Marcora et al., 2005). We could only find one study where the role of 
diet in BC change in RA was evaluated, but no associations between calorie or 
protein intake and muscle parameters were found (Barone et al., 2018).  
The cornerstone in the prevention of age related muscle loss is sufficient 
physical activity (Beaudart et al., 2017; Dent et al., 2018). RA patients tend to be 
physically inactive due to arthralgia, fatigue and stiffness (Sokka T. et al., 2008). 
High intensity resistance training has been shown to improve the outcome of RA, 
including BC (Lemmey et al., 2009, 2009), but these exercise programs are often 
difficult to implement due to low adherence (especially for long-term inter-
vention) (Tournadre et al., 2018). Sarcopenia has a significant impact on quality 
of life. Patients with RA and sarcopenia have a lower quality of life, with health 
assessment questionnaire disability index (HAQ-DI) scores 0.25 units higher on 
average, than those without sarcopenia (Giles, Bartlett, et al., 2008). A recent 
review estimated that the yearly direct medical expenditure due to the impact of 
sarcopenia on disability would be $562 million for the 169,000 US patients with 
RA who were estimated to be sarcopenic, and concluded that finding a pre-RA 
intervention able to prevent or reduce the development of sarcopenia would result 
inconsiderable improvement in physical function and quality of life, and direct 
and indirect cost savings (Giles, 2019). 
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5. STUDY RATIONALE 
RA is still associated with an elevated risk of cardiovascular disease, and the 
resulting premature morbidity, despite the fact that the course of RA has become 
milder due to tight control and aggressive treatment strategies.  
The excess CVD risk associated with RA is only partly explained by tradi-
tional cardiovascular risk factors and inflammatory burdens. Established RA is 
associated with a higher prevalence of cardiometabolic risk factors, but less is 
known about the time of onset of these changes. Cardiovascular mortality has 
been found to be increased in even early RA, leading to a hypothesis that the 
alterations in cardiometabolic risk profile develop in the earliest phase of the 
disease. 
The risk of RA-related CVD is highest in patients with normal body mass for 
reasons not yet fully understood. Patients with higher weight status seem to have 
a lower risk for premature CV mortality – the opposite of what has been found in 
the general population. 
In addition to increased CVD mortality in normal weight patients with RA, there 
seems to be a higher prevalence of cardiometabolic risk factors not predictable 
by weight status. Therefore, we aimed to test the hypothesis that the presence of 
metabolic disturbances in normal weight individuals (metabolic obesity) is 
already present in the early stage of the disease.  
An increasingly frequent cardiometabolic risk factor traditionally associated 
with obesity, insulin resistance has been found to be present in a majority of 
patients with established RA. Prevalence reports in early RA have been rather 
inconsistent, ranging from 1/5 to 3/4 of studied subjects, so we decided to analyze 
this in the Estonian cohort of early RA.  
Little is known about the associations between body composition and IR in 
RA. In established RA, the largest relative difference between the insulin sensitivity 
of controls and patients has been found in the normal weight group, suggesting 
the importance of factors other than obesity in the development of IR in RA. It is 
well known that excess fat is associated with reduced insulin sensitivity, but the 
majority of glucose disposal takes place in lean tissue, supporting the hypothesis 
that altered BC may have a role in the development of IR in RA. Previous studies 
in the field have been limited to reports of associations between BMI and IR in 
RA without detailed analysis of the role of body composition in reduced insulin 
sensitivity. This thesis aims to address that gap in knowledge. 
It is known that in the course of RA, alterations of body composition appear, 
with a decline in lean mass and an increase in fat mass, but it is not clear if these 
changes develop in the preclinical, early stage of RA or later in the course of the 
disease. We could find only a couple studies looking at factors associated with 
body composition in early RA, most taking into account only directly disease-
associated features, such as disease activity and inflammatory markers, with mixed 
results. From the vast data available on aging-related sarcopenia, it is clear that 
chronic inflammation is important in the process, but so are nutrition and physical 
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activity. RA is accompanied by a lack of physical activity due to pain, stiffness 
and fatigue; it is clear that lifestyle factors should be taken into account as well 
when analyzing BC in RA. As muscle loss in established RA seems to be 
irreversible, it is vital to find the factors contributing to the change in the earliest 
stage of the disease to avoid a decrease in quality of life and premature 
cardiovascular mortality. We could not find any published studies where both 
disease associated factors and the role of lifestyle were analyzed in early RA.  
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6. AIMS OF THE THESIS: 
The general aim of this study was to evaluate cardiometabolic risk factors in early 
rheumatoid arthritis. 
This work is focused on body compositional parameters and associations with 
metabolic factors in patients with early rheumatoid arthritis compared to 
population controls. 
 
Specific aims were:  
1. to evaluate the cardiometabolic risk profile in early rheumatoid arthritis by 
assessing the presence and components of metabolic syndrome (Paper I) and 
the prevalence of insulin resistance (Paper II) 
2. to find the factors associated with insulin resistance in early rheumatoid 
arthritis (Paper II) 
3. to assess the body composition of early rheumatoid arthritis patients at disease 
onset compared to population controls (Paper III) 
4. to examine the associations between arthritis disease specific features, physical 
activity, nutritional factors and body composition in early rheumatoid arthritis 
(Paper III) 
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7. SUBJECTS AND METHODS: 
7.1. Subjects 
7.1.1. Early rheumatoid arthritis group 
The thesis is based on a cross-sectional study of 92 patients with ERA. To form 
the study group, 100 consecutive patients referred to Tartu University Hospital 
from January 2012 to May 2014 with a first-ever RA diagnosis and symptom 
duration of up to one year (early arthritis) were invited to participate in the study. 
To be included in the study, the ACR/ EULAR 2012 classification criteria for RA 
(Aletaha et al., 2010) had to be fulfilled. Two patients with other inflammatory 
joint conditions were excluded (one had ankylosing spondylitis, one arthritis 
associated with HCV diagnosed in follow-up). One patient with achondroplasia 
was excluded from data analysis in Paper III due to altered body proportions and 
one patient was excluded from Paper II due to extremely high insulin levels 
(140.9 mU/l).  
No patients in the RA group had concomitant pulmonary conditions, heart 
failure or malignancy considered clinically important by the investigator, although 
one case had treated ovarian cancer in their medical history. 
 
 
7.1.2. Population- based comparison group (Papers II, III) 
350 subjects adjusted for the age and gender composition of the Estonian popu-
lation in 2013 were randomly selected from a primary health care center practice 
list (the total number of subjects was 1854). First, postal invitations with intro-
ductory materials were sent out. A total number of 332 subjects contacted the 
primary health care center for further instruction and were recruited during the 
study period (September 2014–April 2015). Three subjects missed their study 
appointment, eight were excluded due to missing outcome data (seven subjects 
with missing insulin values were excluded from data analysis in Paper II, and one 
subject with no BC data from Papers II, III). The final number of control subjects 
in Paper II: 321, and 328 in Paper III.  
 
 
7.1.3. Matched controls (Paper I) 
The control group consisted of 273 individually age- (+/– 3 years) and sex-matched 
random subjects, selected from a previous population-based cross-sectional 
multicentric study conducted between November 2008 and May 2009 in three 
different Estonian counties (Eglit et al., 2012, 2013). The study population 
consisted of randomly selected adults aged 20–74 years from four primary care 
center practice lists. The initial study population was selected to be representative 
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of the general Estonian population in terms of age and gender. Three controls per 
1 early RA case were selected (1:3 ratio).  
All subjects participating in the study signed written informed consent forms. 
The study was approved by the Research Ethics Committee of the University of 
Tartu (approval no. 
232/M-13, date of approval 03.10.2011; approval no 238/M-15, date of 
approval 16.06.2014) 
 
 
7.2. Methods 
7.2.1. Medical interview 
A face-to-face medical interview was conducted, information on first symptoms 
of arthritis (pain, swelling) was collected, and the onset of patient reported joint 
swelling was considered to be the first definite symptom of RA. The presence of 
concomitant health conditions, including diabetes, cardiovascular disease, and 
treatment with antirheumatic (NSAID, GCS, DMARD), antihypertensive and 
lipid lowering medications was assessed. The time of the first diagnosis of RA 
was confirmed using data in electronical health records and fulfillment of ACR/ 
EULAR 2010 criteria for classification (Aletaha et al., 2010) was evaluated 
retrospectively. 
 
 
7.2.2. Physical examination 
A standardized physical examination was performed. In the RA group, tender and 
swollen joint counts (28 and 42 joint scores) were performed by a certified 
rheumatologist. Body weight was measured in kilograms with an electronic scale, 
subjects wore light indoor clothing without shoes. Height was measured to the 
nearest 0.5 cm using a stadiometer. Waist circumference was measured midway 
between the lower rib margin and the iliac crest. Blood pressure was measured 
after five minutes of sitting with a calibrated sphygmomanometer. 
 
 
7.2.3. Patient reported outcomes 
The quality of life of RA patients was assessed using the standardized Health 
Assessment Questionnaire Disability Index (HAQ-DI) questionnaire, and global 
health was assessed using visual analogue scale (0–100mm).  
Physical activity was measured using the International Physical Activity 
(IPAQ) short form (The IPAQ group, 2003). At least 150 minutes of moderate – 
or 75 minutes of vigorous – physical activity throughout the week was considered 
to be sufficient as recommended by the WHO (WHO, 2010). 
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A 24-hour dietary recall (24HDR) capturing information about foods and 
beverages consumed over the past 24 hours was used to evaluate energy and 
nutrient intake. The 24HDR data was entered into the NutriData software created 
by the Estonian National Institute for Health Development to translate foods and 
beverages in the Estonian food composition database into nutrient equivalents 
(National Institute for Health Development, n.d.).  
 
 
7.2.4. Blood samples 
Blood samples were collected between 8 a.m. and 11 a.m. after an overnight fast. 
Glucose (hexokinase assay), ESR (Westergren method), CRP (immunoturbidi-
metric method), total cholesterol, HDL-cholesterol, and triglycerides were 
measured (enzymatic colorimetric assay) according to standard methodology in 
a local laboratory (United Laboratories of Tartu University Hospital). Sero-
positivity for ACPA and RF was evaluated in the RA group. ACPA was measured 
using electrochemiluminescence assay, using the value of 17k U/L as the cut-off 
for positivity. To measure RF, the immunoturbidimetric method was used and the 
test was considered positive if the RF value was >14 IU/mL. 
Serum was separated from peripheral venous blood samples, stored at –80 C 
until analysis and a panel of metabolic markers, including IL-6, TNF-alpha, and 
insulin was evaluated using Luminex xMAP® technology (Luminex Corp).  
 
 
7.2.5. RA disease activity assessment 
The Disease Activity Score (DAS 28) was calculated according to the standard 
formula, using 28 joint scores, patient global health assessment, and ESR (Papers 
II, III) or CRP values (Paper I) (van Gestel et al., 1998). The patients were grouped 
according to their DAS 28 scores as having remission (DAS 28 score <2.6), low 
disease activity (DAS 28 score <3.2), moderate disease activity (≥3.2 to ≃5.1) or 
high disease activity (>5.1). 
 
 
7.2.6. Cardiometabolic risk profile assessment 
Metabolic syndrome 
To diagnose MetS, the NCEP ATP III criteria (Grundy et al., 2004; “Third Report 
of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) Final Report,” 2002) were used: the syndrome was present 
if at least three of the following criteria were observed: abdominal obesity, 
hypertension, hyperglycemia, hypertriglyceridemia or low HDL.  
The presence of abdominal obesity was defined by waist circumference 
≥102 cm in men and ≥88 cm in women. The subject had hypertension if blood 
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pressure was ≥130/85 mmHg or they were taking antihypertensive medication. 
Hyperglycemia was defined by having fasting glucose: ≥5.6 mmol/L or previously 
diagnosed diabetes. Hypertriglyceridemia was confirmed if TG value was 
≥1.7 mmol/L or the subject was taking lipid-regulating medication; low HDL was 
defined as having HDL cholesterol <1.03 mmol/L in men and <1.30 mmol/L in 
women, or if the patient was currently on drug treatment for reduced HDL.  
Normal weight subjects with metabolic syndrome were classified as normal 
weight metabolically obese. 
 
 
Insulin resistance 
Homeostatic model assessment of IR (HOMA-IR) was calculated according to 
the following formula: fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5 
(Matthews et al., 1985). The cut-off value defined for IR was the 75th percentile 
of the population-based comparison group values. 
 
 
7.2.7. Body composition 
Definition of weight status 
BMI was calculated according to the standard formula – weight in kg divided by 
height in meters squared. BMI groups were formed – normal weight (BMI 
≤ 24.9 kg/m2), overweight (BMI 25–29.9kg/m2), and obese (BMI ≥30 kg/m2), 
according to the WHO criteria (WHO, 2010). 
 
 
Quantification of muscle and fat mass 
Total and regional (left and right arm, left and right leg, trunk, head) BC para-
meters were assessed with a Lunar Prodigy Advance Dual Energy X-Ray 
absorptiometry (DXA) machine for the RA group and the population-based 
comparison group. Fat mass, fat free and muscle (lean) mass were measured. 
Appendicular lean mass was calculated as the sum of lean mass of hands and legs. 
Body fat and lean mass indices were calculated. 
In Paper II, FMI: fat mass index (fat mass kg/height squared); FFM: fat-free 
mass; FFMI: fat-free mass index (fat-free mass/height squared); ALM: appen-
dicular lean mass; ALMI: appendicular lean mass index (appendicular lean mass 
kg/BMI) were calculated. FMI and ALMI were used to assess the role of body 
compositional parameters associated with the presence of insulin resistance. 
In Paper III, body fat percentage (BFP, the fat percentage of total body mass), 
and the appendicular lean mass index ALM/h2 (appendicular lean mass/height 
squared) were calculated. As there is no universal definition for low lean mass in 
RA, we set the cut-off point as having an ALM/h2 less than the 20th percentile of 
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the sex-specific population-based comparison group values (Paper III), corres-
ponding to a threshold value of 8.0586 kg/h2 for males, and 6.0359 kg/h2 for 
females. Overfat was defined as BFP >25% for men and >35% for women 
(WHO, 1997). Using these cut-off values, BC phenotypes were defined: overfat, 
low lean mass, overfat with low lean mass. A subject was classified as having 
healthy BC if both lean and fat mass were within normal values.  
 
 
7.2.8. Statistical analysis 
Statistical analysis was performed using SPSS v. 22–24 (IBM Corp., USA). Two-
tailed tests and a 5% significance level with Bonferroni correction for multiple 
comparisons were used in all analyses. 
Methods of descriptive statistics as means and standard deviations were used 
for continuous variables, categorical variables were presented in counts and 
percentages. 
Odds Ratios (OR), the Chi-square test, and Fisher’s exact test were used to 
compare frequencies of categorical variables. Student's T-test for normally dis-
tributed data, and the Mann-Whitney U test for non-parametric data, were used 
to compare means.  
Binomial logistic regression was performed to ascertain the effects of subject 
characteristics on the likelihood of being classified as insulin resistant (Paper II), 
the effects of age and gender adjusted subject characteristics on the likelihood of 
low lean mass and the associations between ERA and BC phenotypes (Paper III). 
The linearity of the continuous variables with respect to the logit of the dependent 
variable was assessed via the Box-Tidwell (1962) procedure. 
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8. RESULTS 
8.1. Demographic and clinical laboratory characteristics 
Mean age in the RA group was 52 years (19–77), 72% were female, and male 
patients were slightly older (55±3 years) than females (52±2 years).  
The majority of RA patients were seropositive for ACPA (88%) and/or RF 
(88%). The mean time elapsed from the onset of self-reported synovitis was 
201±58 days, and the mean time from diagnosis was 26.8±10.3 days.  
Most of the patients had active disease – approximately 30% had high, 40% 
moderate and 30% low disease activity (classified according to the ACR 
recommendations (Anderson et al., 2012)). Mean DAS28 score was 4.8±0.3, 
mean ESR was 20.3±2.3 mm/h, and CRP 12.3±2.0 g/l, mean swollen joint count 
4.8±0.6 and tender joint count 10.6±0.9. 
Male RA patients had higher disease activity, higher levels of inflammatory 
markers, and a higher proportion of ACPA and RF seropositivity compared to 
women. 
More than half of the subjects (56%) had started DMARD therapy by the time 
of the study visit, about one fourth (28%) were on glucocorticoid treatment, with 
a mean dosage of 13.8±1.2mg prednisolone a day.  
Characteristics of the matched controls (Paper I): 273 subjects participating in 
the study as matched controls were age/gender matched to patients in the early 
RA group. The mean age of the subjects was 51.5±2 years, 72.5% were female. 
Characteristics of the population-based comparison group (Papers II, III): The 
mean age of the group was 48±1years, 54% of the subjects were female. There 
was a statistically significant difference between demographics (age, gender) in 
the control and early RA group. There were more women in the RA group, and 
subjects in the control group were younger (p<0.05). 
 
 
8.2. Cardiometabolic risk profile 
8.2.1. Metabolic syndrome 
Components of metabolic syndrome in patients with early RA and matched 
controls (Paper I) 
There was no statistically significant difference between the early RA and 
age/gender matched control group in mean BMI values or the presence of MetS 
– 35.2% of the ERA subjects were classified as having MetS, as were 34.1% of the 
controls (Table 1).  
Patients with early RA had higher mean systolic and diastolic blood pressure 
values than controls. 72.5% of the early RA patients and 61.2% of the controls 
were classified as having hypertension. Looking at the proportion of subjects with 
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treated hypertension, we found that only 30.8% RA patients received anti-
hypertensive treatment compared to the majority – 52.6% of the control subjects 
with elevated blood pressure.  
There was no difference in the prevalence of abdominal obesity, hyperglycemia, 
or dyslipidemia between the two groups. 
 
Mean, ± SD unless otherwise stated. Statistically significant differences p < 0.05. TG – trigly-
cerides, HDL – high density lipoprotein, NS – non-significant 
Note: Adapted from Müller R et al. The metabolic profile in early rheumatoid arthritis: a high pre-
valence of metabolic obesity. Rheumatol Int. 2017 Jan;37(1):21–27. Springer-Verlag Berlin 
Heidelberg 
 
Among the RA group, we found no difference between patients with and without 
MetS in the disease activity parameters (DAS 28 value, swollen, tender joint 
count, SR, and CRP), disease duration, NSAID, or glucocorticoid treatment. 
  
 
 
Table 1. Cardiometabolic risk factors in early RA group and control subjects  
Early RA
N= 91 
Control 
group 
N= 273 OR (95% CI) p 
BMI (kg/h2) 27.1 (5.6) 28.2 (6.3) NS 
Normal weight N (%) 36 (40.0%) 88 (32.6%) 1.4 (0.8, 2.2) NS 
Overweight N (%) 31 (34.4%) 86 (31.9%) 1.1 (0.7, 1.9) NS 
Obese N (%) 23 (25.6%) 96 (35.6%) 0.6 (0.4, 1.1) NS 
Metabolic syndrome N (%) 32 (35.2%) 93 (34.1%) 1.0 (0.6, 1.7) NS 
Systolic blood pressure (mmHg) 137 (22) 131 (19) 0.01 
Diastolic blood pressure (mmHg) 85 (12) 81 (10) <0.01 
Hypertension N (%) 66 (72.5%) 167 (61.2%) 1.7 (0.9, 2.8) 0.05 
Waist circumference (cm) 90 (13) 92 (16) NS 
Abdominal obesity N (%) 43 (47.3%) 133 (48.7%) 0.9 (0.6, 1.5) NS 
Fasting glucose (mmol/l) 5.3 (0.7) 5.4 (0.8) NS 
Hyperglycemia N (%) 28 (30.8%) 87 (31.9%) 0.9 (0.6, 1.5) NS 
HDL cholesterol (mmol/l) 1.6 (0.5) 1.6 (0.5) NS 
Low HDL N (%) 23 (25.3%) 67 (24.5%) 1.0 (0.6, 1.6) NS 
Triglycerides (mmol/l) 1.2 (0.6) 1.3 (0.7) NS 
High TG N (%) 21 (23.1%) 64 (23.4%) 0.9 (0.5, 1.6) NS 
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Components of metabolic syndrome by weight status 
Components of MetS in normal and obese subjects are shown in Table 2. When 
looking into the data of normal weight subjects, the odds of being classified as 
metabolically obese were 5.6 times higher for early RA subjects compared to 
controls. Of the individual components of metabolic syndrome normal weight RA 
subjects had higher odds of having hypertension (OR 2.8) and hyperglycemia 
(OR 2.9) compared to controls. In this group, the proportion of both RA patients 
and controls with hypertension and receiving antihypertensive medication was 
low – 17% of RA patients and 33% of the control subjects were treated.  
As expected, almost half of the overweight/obese subjects had MetS. The 
prevalence of MetS and all of its components (hypertension, abdominal obesity, 
low HDL, high TG and hyperglycemia) was higher among overweight/obese 
subjects in both groups, without a significant difference between early RA and 
control subjects. 
 
Table 2. Prevalence of metabolic syndrome and metabolic risk factors in normal-weight 
and overweight sub-groups of early RA subjects and the control group 
Normal weight Overweight/obese 
Early 
RA 
N=36 
Control 
group 
N= 88 
OR 
(95%CI) 
Early 
RA 
N=55 
Control 
group 
N=185 
OR 
(95%CI) 
Metabolic 
syndrome 
6 (16.7) 2 (2.3) 5.6 
(1.3, 23.8)
26 (47.3) 91 (49.2) 0.9 
(0.5, 1.7) 
Hypertension 21 (58.3) 27 (30.7) 2.8 
(1.3, 6.0) 
45 (81.8) 137 (74.1) 1.6 
(0.7, 3.3) 
Abdominal 
obesity 
3 (8.3) 2 (2.3) 3.9 
(0.6, 24.2)
40 (72.7) 131 (70.8) 1.1 
(0.6, 2.3) 
Low HDL 4 (11.1) 11 (12.5) 0.7 
(0.2, 2.4) 
19 (34.5) 56 (30.3) 1.2 
(0.6, 2.2) 
High TG level 6 (16.7) 10 (11.4) 1.5 
(0.5, 4.6) 
15 (27.3) 54 (29.2) 0.9 
(0.4, 1.7) 
Hyperglycemia 9 (25.0) 8 (9.1) 2.9 
(1.0, 8.0) 
19 (34.5) 79 (42.7) 0.7 
(0.4, 1.4) 
N (%) Statistically significant differences shown in boldface type (p <0.05). TG – triglycerides, 
HDL – high density lipoprotein 
Note: Adapted from Müller R et al. The metabolic profile in early rheumatoid arthritis: a high 
prevalence of metabolic obesity. Rheumatol Int. 2017 Jan;37(1):21–27. Springer-Verlag Berlin 
Heidelberg 
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8.2.2. Insulin resistance 
Insulin resistance in the RA and population-based comparison groups 
(Paper II) 
There was no difference in glucose values between the early RA and control group. 
The patients with ERA had significantly higher mean insulin values, higher 
HOMA-IR scores; and a higher proportion of insulin resistance – 55% of the ERA 
patients were classified as being insulin resistant, compared to 25% of the control 
subjects (Table 3.). 
Male subjects were more likely to be classified as insulin resistant than 
females.73% of the males in RA group were insulin resistant, compared to 28% 
among the controls. 
 
Factors associated with insulin resistance (Paper II) 
Looking into the unadjusted characteristics of IR and non-IR RA patients, those 
classified as being insulin resistant had higher inflammatory markers (CRP, TNF-
alpha, and IL-6) and higher disease activity (Table 4). The mean DAS 28 score 
in the non-IR group was 3.6±0.2, and 4.6±0.2 in the IR group. 43% of the insulin-
resistant patients had high disease activity compared to 12% of the non-insulin 
resistant group.  
 
 
 
Table 3. Insulin sensitivity in early RA subjects and control group 
 
Gender 
Male Female Total 
Early RA 
N= 26 
Control
group 
N= 148 
Early 
RA 
N= 66 
Control
group 
N= 173 
Early 
RA 
N= 92 
Control 
group 
N= 321 
Glucose (mmol/l) 5.3 (0.1) 5.4 (0.1) 5.3 (0.1) 5.2 (0.1) 5.3 (0.1) 5.3 (0.0) 
Insulin (mU/l) 15.3 (1.9) 7.2 (0.4) 13.2 (2.2) 6.9 (0.4) 13.8 (1.6) 7.0 (0.3) 
HOMA-IR score 
(units) 
3.6 (0.4) 1.8 (0.1) 3.1 (0.5) 1.7 (0.1) 3.2 (0.4) 1.7 (0.1) 
Insulin  
resistant N (%) 
19 (73.1) 41 (27.7) 32 (48.5) 39 (22.5) 51 (55.4) 80 (24.9) 
Values are the mean, ± S.E. if not stated otherwise. Statistically significant differences shown in 
boldface type (p <0.05). HOMA-IR – homeostatic model assessment for insulin resistance,  
Note: Adapted from Müller R, et al. Insulin Resistance in Early Rheumatoid Arthritis Is Associated 
with Low Appendicular Lean Mass. Biomed Res Int. 2017;2017:9584720 (licensed under Creative 
Commons) 
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Mean, ± S.E. if not stated otherwise, statistically significant differences p < 0.05. BMI – body mass 
index, CRP – C-reactive protein, TNF-alpha – tumor necrosis factor alpha, IL-6 – interleukin 6, 
RF-rheumatoid factor, DAS28 – disease activity score calculated using 28 joints, GCS – gluco-
corticosteroid, FMI – fat mass index (fat mass kg/ height h2), ALM – appendicular lean mass, ALMI – 
appendicular lean mass index (appendicular lean mass kg/BMI), NS – non-significant 
Note: Adapted from Müller R et al. Insulin Resistance in Early Rheumatoid Arthritis Is Associated 
with Low Appendicular Lean Mass. Biomed Res Int. 2017;2017:9584720 (licensed under Creative 
Commons) 
 
The presence of IR was independently associated with gender, RA group, FMI, 
and ALMI (according to binomial logistic regression). Early RA patients had 4.8 
times higher odds of being classified as insulin resistant¸ and males had 7.7 times 
higher odds of exhibiting insulin resistance than females (Table 5). 
 
 
 
Table 4. Characteristics of non-insulin resistant and insulin resistant early RA patients 
 Non-insulin 
resistant  
N=41 
Insulin 
resistant  
N=51 p 
Age (years) 51 (2) 54 (2) NS 
Male gender N (%) 7 (17.1) 19 (37.3) 0.02 
BMI (kg/h2) 26.3 (0.8) 27.9 (0.9) NS 
CRP (mg/l) 8.6 (3.0) 14.5 (2.4) 0.01 
TNF-alpha (pg/ml) 2.1 (0.1) 3.4 (0.4) 0.001 
IL-6 (pg/ml) 8.6 (4.2) 23.2 (5.3) <0.001 
RF positive N (%) 25 (61.0) 39 (76.5) NS 
ACPA positive N (%) 25 (61.0) 38 (74.5) NS 
DAS28 score (units) 3.6 (0.2) 4.6 (0.2) 0.003 
Low disease activity N (%) 18 (45.0) 11 (21.6) 0.02 
Moderate disease activity N (%) 18 (43.9) 18 (35.3) NS 
High disease activity N (%) 5 (12.2) 22 (43.1) 0.001 
Current GCS usage N (%) 10 (25.0) 16 (31.4) NS 
Current DMARD usage N (%)  24 (58.5) 27 (52.9) NS 
Disease duration (days) 234.7 (37.5) 199.5 (32.3) NS 
Total fat mass (kg) 26.2 (1.7) 28.1 (1.6) NS 
FMI (kg/h2) 9.5 (0.6) 10.6 (0.7) NS 
ALM (kg) 18.7 (0.6) 19.3 (0.6) NS 
ALMI (kg/BMI) 0.73 (0.03) 0.72 (0.03) NS 
41 
Statistically significant differences p < 0.05. Age groups <29 and 30–49 compared to >50. FMI – 
fat mass index (fat mass kg/ height h2), FFMI – fat-free mass index (fat-free mass/ height m2), 
ALMI – appendicular lean mass index (appendicular lean mass kg/BMI), NS – non-significant 
Note: Adapted from Müller R, et al. Insulin Resistance in Early Rheumatoid Arthritis Is Associated 
with Low Appendicular Lean Mass. Biomed Res Int. 2017;2017:9584720 (licensed under Creative 
Commons) 
 
Using binomial logistic regression to determine the variables associated with IR 
in the ERA group, we found that men had 7.4 times higher odds of being insulin 
resistant than females, and patients with high disease activity had 6.2 times higher 
odds of having IR than those with low disease activity. Lower ALMI was 
associated with an increased likelihood of IR (Table 6). 
Statistically significant differences p < 0.05. ALMI – appendicular lean mass index (appendicular 
lean mass kg/BMI), TNF-alpha – tumor necrosis factors alpha, DAS 28 – disease activity score 
based on 28 joints, NS – non-significant 
Note: Adapted from Müller R et al. Insulin Resistance in Early Rheumatoid Arthritis Is Associated 
with Low Appendicular Lean Mass. Biomed Res Int. 2017;2017:9584720 (licensed under Creative 
Commons) 
 
 
 
Table 5. The effects of age, gender, body composition indices and having early RA, on 
the likelihood of IR 
 B ± S.E. OR 95% CI p 
RA group 1.57 0.31 4.80 2.61, 8.82 <0.001 
Male gender 2.04 0.54 7.70 2.69, 22.08 <0.001 
Age group <29 0.53 0.44 1.69 0.71, 4.0 NS 
Age group 30–49 –0.22 0.31 0.80 0.44, 1.47 NS 
FMI 0.20 0.06 1.21 1.08, 1.38 0.002 
FFMI 0.07 0.08 1.08 0.92, 1.27 NS 
ALMI –3.02 1.57 0.05 0.002, 1.06 0.05 
 
Table 6. Summary of binary logistic regression analysis for variables predicting insulin 
resistance in the early RA group 
 B ± S.E. OR 95% CI p 
Male gender 2.0 0.80 7.35 1.55, 34.91 0.01 
ALMI  –3.45 1.74 0.03 0.001, 0.97 0.05 
TNF-alpha (pg/ml) 0.42 0.26 1.52 0.91, 2.53 NS 
High DAS 28 score 1.82 0.65 6.19 1.72, 22.2 0.005 
Moderate DAS28 score 0.48 0.53 1.62 0.57, 4.59 NS 
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8.2.3. Body composition 
Body composition in RA patients and controls (Papers II and III) 
There was no difference in BMI values between the matched controls and ERA 
group (Paper I).  
There were more men among the population-based comparison group (Papers 
II and III), resulting in a taller and heavier group, but there was no difference in 
the mean BMI values or prevalence of overweight or obesity between the groups.  
Of the BC parameters, patients with ERA had lower muscle indices – lower 
fat-free, appendicular lean mass and appendicular lean mass adjusted for body 
size (ALM/BMI or ALM/h2) as shown in Table 7. There was no difference between 
unadjusted body fat values between the groups.  
Values are the mean, ± S.E. Statistically significant differences p < 0.05. BFP: Body Fat Percentage – 
fat % of total body mass); trunk fat % – percentage of trunk fat of total fat; appendicular fat % – 
percentage of appendicular fat of total fat; ALM –Appendicular Lean Mass; ALM/h2 – ALM 
/height2), NS – non-significant  
Note: Adapted from Müller R et al. Factors Associated With Low Lean Mass in Early Rheumatoid 
Arthritis: A Cross-Sectional Study. Medicina (Kaunas). 2019 Nov 8;55(11) (licensed under 
Creative Commons) 
 
 
 
 
 
 
 
 
Table 7. Body composition in early RA patients and controls 
 
 
Early 
RA 
N=91 
 
Control 
Group 
N = 328 
 Male  Female  
p 
Early 
RA 
N= 25 
Control 
Group
N = 151 p 
Early 
RA 
N= 66 
Control 
Group 
N = 171 p 
Fat mass 
(kg) 
27.3 
(1.1) 
26.5 
(0.6) 
NS 22.5 
(1.9) 
24.1 
(0.9) 
NS 29.2 
(1.3) 
28.5 
(0.9) 
NS 
BFP 36.0 
(1.0) 
29.4 
(0.6) 
< 0.001 27.2 
(1.7) 
21.9 
(0.6) 
0.002 39.3 
(0.9) 
35.6 
(0.7) 
0.007 
Trunk fat % 53.6 
(0.7) 
55.8 
(0.4) 
0.01 59.3 
(1.2) 
60.7 
(0.5) 
0.01 51.5 
(0.7) 
51.6 
(0.4) 
NS 
Appen- 
dicular fat % 
43.1 
(0.7) 
40.9 
(0.4) 
0.01 37.0 
(1.1) 
35.9 
(0.4) 
NS 45.4 
(0.7) 
45.2 
(0.4) 
NS 
ALM (kg) 19.0 
(0.4) 
22.9 
(0.3) 
< 0.001 23.7 
(0.6) 
28.5 
(0.3) 
< 0.001 17.2 
(0.3) 
18.1 
(0.2) 
0.01 
ALM/h2 6.8 
(0.1) 
7.7 (0.1) < 0.001 7.7 
(0.2) 
8.8 
(0.1) 
< 0.001 6.4 
(0.1) 
6.7 
(0.1) 
0.03 
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When adjusted for age and gender, ERA patients had higher mean BFP, lower 
ALM values and higher odds of having unhealthy BC. 41.8% of the ERA patients 
and 19.8% of the controls had low lean mass (Table 8). 68.1% of the ERA 
subjects and 47.3% of the controls had a high body fat percentage and were 
classified as overfat. The adjusted odds of having the least favorable BC profile – 
sarcopenic overfat – were 4.4 times higher among the ERA group. The control 
subjects had 2.9 times higher odds of being neither sarcopenic nor overfat and 
being classified as having healthy BC than age- and gender-adjusted patients with 
ERA. 
Age, gender adjusted odds ratio (aOR) for early RA group (binary logistic regression) healthy BC – 
normal lean mass, normal fat mass; low lean mass – low appendicular lean mass; overfat – high 
body fat percentage.  
Note: Adapted from Müller R et al. Factors Associated With Low Lean Mass in Early Rheumatoid 
Arthritis: A Cross-Sectional Study. Medicina (Kaunas). 2019 Nov 8;55(11) (licensed under 
Creative Commons) 
 
 
Factors associated with altered BC (Paper III) 
Patients with ERA consumed less total food kilocalories per day (1534± 69) 
compared to the controls (1841±44; p = 0.001). Both men and women with ERA 
had lower daily protein intake, ERA patients consumed in average 23g less 
protein in a day compared to population controls (p < 0.001). Women with ERA 
consumed also less fat (the difference in males did not reach statistical signi-
ficance), resulting in the mean daily fat intake in the ERA group 16 g lower 
compared to the control group (p = 0.001).  
28% of men with ERA reached sufficient physical activity level recommended 
by the WHO compared to 64.2% of the control group (p = 0.01). However, over 
half (53%) of the women with ERA were sufficiently physically active, as were 
only 40.7% of the women in the control group (p = 0.01).  
 
Table 8. Prevalence and age, gender adjusted odds for body composition phenotypes.  
 Early RA N = 91 
Control group 
N = 328  aOR 
(95% CI) p  N (%) 95% CI N (%) 95% CI p 
Healthy 
BC 
15 (16.5) 10.0, 25.1 130 (39.6) 34.5, 45.0 < 0.001 0.4 (0.2, 0.7) 0.01 
Low lean 
mass 
38 (41.8) 32.0, 52.0 65 (19.8) 15.8, 24.4 < 0.001 3.3 (1.9, 5.5) < 0.001 
Overfat 62 (68.1) 58.1, 77.0 155 (47.3) 41.9, 52.7 < 0.001 1.9 (1.1, 3.3) 0.02 
Low lean 
mass+ 
overfat 
24 (26.4) 18.2, 36.1 23 (7.0) 4.6, 10.2 < 0.001 4.4 (2.3, 8.4) < 0.001 
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The factors associated with low lean mass differed between the groups 
(Table 9). Higher odds of having low lean mass in the ERA group were associated 
with higher inflammatory activity – ESR and CRP value, lower protein intake, 
corticosteroid usage, and lower quality of life (higher HAQ-DI score) after adjust-
ment to age and gender.  
In the control group, the low ALM was associated with age, insufficient 
physical activity, and smoking. 
aOR: age, gender adjusted odds ratio (binary logistic regression) *: Unadjusted; HAQ score – Health 
Assessment Questionnaire; DAS 28 – Disease Assessment Score 28; RF – Rheumatoid Factor; 
ACPA – Anti-cyclic Citrullinated Peptide Antibodies; GCS – glucocorticosteroid; DMARD – 
Disease-Modifying Anti-Rheumatic Drug; sufficient physical activity – > 150 min moderate/75 min 
vigorous activity/week; ND – not done. 
Note: Adapted from Müller R et al. Factors Associated With Low Lean Mass in Early Rheumatoid 
Arthritis: A Cross-Sectional Study. Medicina (Kaunas). 2019 Nov 8;55(11) (licensed under 
Creative Commons) 
  
Table 9. Factors associated with low lean mass in the early RA and control group adjusted 
for age and gender. 
 Early RA Control group 
 OR 95% CI p OR 95% CI p 
Age (years)* 1.00 0.98, 1.03 0.77 0.98 0.96, 0.99 0.006 
Gender (male) * 2.23 0.87, 5.68 0.09 1.01 0.59, 1.75 0.96 
ESR (mm/h) 1.026 1.002, 1.051 0.03 ND   
CRP (mg/l) 1.032 1.002, 1.063 0.04 0.99 0.91, 1.07 0.74 
HAQ score (units) 2.41 1.24, 4.65 0.009 ND   
25 (OH) vitamin D (nmol/l) 1.00 0.98, 1.02 0.84 0.99 0.98, 1.01 0.30 
Tender joint count (N/44) 1.02 0.97, 1.08 0.39 ND   
Swollen joint count (N/44) 1.03 0.95, 1.12 0.53 ND   
DAS 28 score (units) 1.22 0.91, 1.63 0.18 ND   
RF positive 1.10 0.42, 2.88 0.84 ND   
ACPA positive 1.20 0.46, 3.13 0.71 ND   
Current GCS user 3.71 1.39, 9.94 0.009 ND   
Current DMARD user 1.29 0.54, 3.09 0.57 ND   
Time from first symptoms 1.00 1.00, 1.00 0.55 ND   
Insufficient physical 
activity 
0.51 1.00, 1.34 0.17 2.99 1.64, 5.46 <0.001 
Smoking (ever) 1.40 0.53, 3.67 0.50 2.35 1.27, 4.33 0.006 
Protein intake (g/day) 0.98 0.96, 0.99 0.04 1.00 0.99, 1.00 0.43 
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9. DISCUSSION 
9.1. Cardiometabolic risk profile in early RA 
9.1.1. Metabolic syndrome in early RA 
The first aim of our study was to evaluate the cardiometabolic risk profile of 
subjects with early RA. The results of the study (paper I) indicate that metabolic 
co-morbidities of RA develop in the initial stage of the disease and are associated 
with altered body composition. 
MetS is an important CVD risk factor linked to increased weight in the general 
population and in established RA, MetS has been found to be associated with 
subclinical atherosclerosis as well (Burggraaf et al., 2018).The prevalence of 
MetS in our early RA group was similar to what has been found previously in 
established disease (Zhang et al., 2013). We did not find a difference in the rate 
of MetS between RA (35.2%) and age/gender matched subjects in the control 
group (34.1%). There seems to be a significant heterogeneity in the presence of 
MetS in the general population, depending on the geographical region or 
population studied (Saklayen, 2018). It is reasonable to believe that the same 
applies to MetS in RA as well. To our knowledge, this is the first study evaluating 
MetS in a European early RA group.  
 
 
Presence of metabolic syndrome according to body weight 
Confirming the association between obesity and MetS, the prevalence of MetS 
and its components was significantly higher in overweight/obese subjects in both 
of our study groups. A new finding was that the odds of having MetS were 5.6 
times higher among the RA group with normal weight- a phenomenon called 
normal weight metabolic obesity, while MetS was rare in controls in the same 
weight group. There is no standard definition for normal weight metabolically 
unhealthy/obese phenotype where a lean person carries multiple cardiometabolic 
risk factors traditionally associated with obesity (Ding et al., 2016). In previous 
studies, the rate of normal weight metabolic obesity in general population has 
ranged from 5% to 45% (Ding et al., 2016; N. Eckel et al., 2015; Mathew et al., 
2016). This phenomenon has not been previously described in early RA. Data on 
the long-term outcomes of this unhealthy phenotype is limited, but it has been 
associated with increased markers of atherosclerosis, higher prevalence of non-
alcoholic fatty liver disease, subclinical systolic, diastolic dysfunction and angio-
graphic coronary artery disease (Mathew et al., 2016).  
The presence of metabolic obesity in early RA patients with normal weight 
may contribute to the “obesity paradox” in RA, a higher CVD risk in patients 
with normal weight (Baker et al., 2015; England, Baker, et al., 2018) associated 
with a change in BC and an excess of metabolically active fat tissue in RA patients 
with normal BMI, as reported in previous studies (Book et al., 2009; Giles et al., 
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2010). The pathophysiological background and long-term consequences of the 
normal-weight metabolically obese phenotype present in the early stage of RA 
should be established in future studies.  
 
 
Components of metabolic syndrome 
An important finding in early RA group reported in paper I was a high prevalence 
of hypertension – one of the strongest predictors of cardiovascular disease. 
Hypertension was found in a higher proportion of early RA patients (73%) 
compared to controls (61%). In previous studies, the reported prevalence of 
hypertension in RA has been widely variable, ranging from 4% to 73% (Boyer et 
al., 2011; Nurmohamed et al., 2015). In our study the difference between RA 
patients and control group was especially substantial in the normal BMI sub-
group, in which early RA patients had 2.8 times higher odds of having hyper-
tension compared to age/gender matched controls. This result differs from the 
findings of an earlier study that associated hypertension in RA mainly with obesity 
(Morović-Vergles et al., 2013). Even more concerning was the fact that the pro-
portion of patients with elevated blood pressure but without antihypertensive 
treatment was significantly higher among RA patients. Only 31% of RA patients 
with elevated blood pressure received treatment, compared to 53% of controls with 
hypertension. This is in line with reports of several previous groups describing 
low prevalence of treated hypertension in RA (proportion of patients with hyper-
tension and receiving treatment ranging from 22% to 34%) (Panoulas et al., 2008). 
Blood pressure can be increased in RA due to the effect of chronic inflammation, 
altered body composition, insulin resistance, and increased peripheral resistance 
due to atherosclerosis, but also due to NSAID use and low physical activity 
(Panoulas et al., 2008). Which of these factors is the main underlying mechanism 
leading to hypertension in early arthritis needs further in-depth analysis in larger 
cohorts. Hypertension is a condition of established importance in the develop-
ment of CVD that can be easily and noninvasively diagnosed and treated. Blood 
pressure monitoring should be a routine procedure in the follow-up of all patients 
with RA from the initial stage of the disease, as now recommended by EULAR 
(Agca et al., 2017). 
Previous studies have shown an association between RA, hyperglycemia and 
diabetes. The odds of diabetes in RA have been reported to be 1.74 times higher 
compared to the general population and the difference is believed to be induced 
mainly by the presence of IR (Boyer et al., 2011; Nicolau et al., 2017). Diabetes is 
a recognized independent risk factor for CVD in RA as well as in the general 
population (Chung et al., 2008; Patel et al., 2016). In our study, there was no 
difference between the rates of hyperglycemia, diabetes or obesity in the early 
RA and control subjects. Looking into the normal-weight subgroup, patients with 
early RA had a significantly higher prevalence of hyperglycemia compared to 
controls, pointing to the role of altered body composition and the possible role 
played by hidden IR (Chung et al., 2008; Zhang et al., 2013).  
47 
9.1.2. Insulin resistance in early RA 
In paper II of this study, we aimed to fill the gap in knowledge around evaluating 
the presence of IR in early RA. The prevalence of IR is rising worldwide due to 
obesity epidemics as the decrease in the general population’s insulin sensitivity 
is primarily associated with increased weight (Abbasi et al., 2002; Martinez et al., 
2017). The association between established RA and IR is well known (Nicolau et 
al., 2017), but only a few studies have looked into this in the early stage of the 
disease, with inconclusive results (AbouAssi et al., 2014; Manrique-Arija et al., 
2015; Mirjafari et al., 2011; Shahin et al., 2010). In our group, early RA patients 
had 4.8 times higher odds of having IR compared to the general population 
(adjusted to age and gender). Due to methodological differences (criteria for RA 
and IR, and cut-off points) studies conducted to evaluate the prevalence of IR in 
ERA are hard to compare. Frequently observed IR in the initial stage of RA is of 
high importance, as IR in the general population is considered to be one of the most 
important contributors to CVD. In RA, the topic is a bit more controversial. Some 
groups have confirmed the associated risk, and others have denied an association 
between the presence of IR in RA and elevated CV risk (Chung et al., 2008; Giles 
et al., 2015; González-Gay et al., 2015; Guin et al., 2019; Montagna et al., 2007), 
but data from long-term observational studies is currently not available.  
 
 
9.1.3. Factors associated with IR in early RA 
Differences between the groups were the most remarkable among male ERA 
patients and controls (men with ERA had 7.4 times higher odds of being classified 
as insulin resistant than women of the same group). The association between male 
gender and IR has been noted in the general population but gender differences in 
the presence of IR in RA have not been described before. The difference in BC 
with elevated visceral adipose tissue compared to women, lower adiponectin 
levels, and inflammation induced decrease in androgen levels, are believed to be 
the main contributing factors to the higher prevalence of IR among men (Geer & 
Shen, 2009; Rao et al., 2013) and could be the factors contributing to the dif-
ference between men and women, to an even higher extent in RA.  
Additionally, looking into the associations between BC and IR, we found that 
lower appendicular lean mass was indeed associated with IR in the ERA group, 
but not in the control group. Several previous studies have shown the relationship 
between adipose tissue and IR in ERA, and adipose tissue is thought to be the 
main factor responsible for IR in the general population (AbouAssi et al., 2014; 
Martinez et al., 2017; Mirjafari et al., 2011). To our knowledge, this is the first 
study showing an increased likelihood of IR in ERA associated with lower muscle 
mass. The role of skeletal muscle loss in the development of IR has been shown 
in the general population (Srikanthan et al., 2010; Srikanthan & Karlamangla, 
2011). The concept of BC change, loss of lean mass, and gain in fat tissue in RA 
is well established (Challal et al., 2015; Santo et al., 2018). Muscle mass is an 
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important determinant of glucose and energy homeostasis (Cleasby et al., 2016). 
The relationship of IR and sarcopenia has been described as a self-contained loop 
where loss of muscle is associated with intramuscular fat infiltration and enhanced 
production of inflammatory cytokines, as well as lipotoxicity, mitochondrial dys-
function, oxidative stress, and anabolic resistance leading to IR. In turn, these 
disturbances exacerbate sarcopenia (Cleasby et al., 2016; Tournadre et al., 2017, 
2018).  
The results of our study concerning disease-specific measures and IR were 
quite expected and similar to what has been found before. IR in RA has been 
associated with unfavorable prognostic markers – disease activity, seropositivity, 
and higher inflammatory activity (Nicolau et al., 2017). We found that IR was 
associated with higher levels of inflammatory markers (CRP, TNF-alpha, and IL-
6), and higher disease activity, but did not see an association with seropositivity. 
In a multivariate model, high disease activity (DAS28 score) remained statisti-
cally significant, confirming the association between high inflammatory burden 
and IR. High disease activity in the early stage of the disease is associated with 
worse prognosis, and our findings suggest that IR is tightly connected to adverse 
RA outcomes, and could be the reason behind a rise in cardiovascular mortality 
in the early stage, with elevated risk in patients with a higher inflammatory burden 
(Gonzalez et al., 2008; Goodson et al., 2004; Humphreys et al., 2014). 
 
 
9.1.4. Body composition in early RA 
The third paper focused on the differences in BC between early RA and control 
subjects, concentrating on factors associated with changes in lean mass. To our 
knowledge, this is the first study that has assessed both the role of lifestyle (diet 
and physical activity) and disease specific parameters in association with low lean 
mass in ERA. 
The majority of patients with established RA are affected by BC alteration – 
lean mass loss and fat mass gain (Rall & Roubenoff, 2004; Summers et al., 2010) – 
but only a couple of studies have looked into this phenomenon in early RA (Book 
et al., 2009; Dao et al., 2011; Turk et al., 2018). We found that the BC of patients 
with recent onset RA differs from control subjects- ERA patients have lower 
appendicular lean mass, higher body fat percentage, and a higher prevalence of 
unhealthy BC phenotypes. 42% of subjects in the ERA group were classified as 
having low lean mass, 68% had a high body fat percentage, and 26% had the least 
favorable BC phenotype: a combination of low lean mass and overfat. Only 16% 
of patients with ERA had no unhealthy BC components. Our results confirm that 
the change in BC in RA develops early in the course of the disease (Book et al., 
2009; Dao et al., 2011; Turk et al., 2018). The mean ALM values reported by a 
Swedish ERA study were quite similar to the ones found by us –17.2 kg in women 
and 22.5 kg in men, compared to 17.2 kg and 23.7 kg respectively in our study) 
(Book et al., 2009). Population-specific differences in BC parameters make direct 
comparisons with other groups difficult. For example, people originating from 
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Asia tend to have a higher fat mass and lower lean mass in relation to BMI 
compared to people of European origin. In a study evaluating BC in Vietnamese 
women with ERA, the mean ALM was 12.9 kg (Dao et al., 2011). In a recent 
early arthritis study in the Netherlands, a 5–7% lower ALM was found in 
DMARD naïve early arthritis patients compared to age matched controls, but only 
data from subjects over the age of 50 was analyzed (Turk et al., 2018). These 
results hint that the obesity paradox – elevated CVD risk in normal weight 
patients – can already be mediated by alteration in BC in the disease’s early stage. 
To confirm the hypothesis, long-term observational studies looking into markers 
of subclinical atherosclerosis and CVD mortality are needed. 
 
 
9.1.5. Factors associated with BC in early RA 
In our study, the presence of low lean mass was not associated with the duration 
of symptoms of arthritis, suggesting that disease-specific pre-clinical factors are 
the main contributors to the change. A Swedish study (Book et al., 2009) found 
an association between disease duration and lower lean mass in females in its 
initial evaluation, but a follow-up after two years (Book et al., 2011) came to the 
conclusion that age-related loss of lean mass and gain in fat mass are less expressed 
in RA compared to controls. A group in the Netherlands controversially found that 
a longer symptom duration was associated with a higher lean (and fat) mass, but 
only in male subjects (Turk et al., 2018).  
In light of the knowledge that BC change in RA leads to a cascade of metabolic 
abnormalities, including insulin resistance and metabolic syndrome, enhancing 
endothelial dysfunction and leading to elevated cardiovascular risk (Challal et al., 
2015; Delgado-Frías et al., 2015; Elkan et al., 2009), the findings in the initial 
stage of the disease emphasize the need to find an efficient intervention to prevent 
changes in BC.  
Inflammation induced catabolism is considered to be responsible for the devel-
opment of the loss of lean tissue and fat accumulation characteristic to established 
RA (Engvall et al., 2008; Rall & Roubenoff, 2004; Summers et al., 2010). Sar-
copenia is a recognized comorbidity in several other chronic inflammatory condi-
tions, low-grade chronic inflammation is associated with biologic aging, and higher 
levels of CRP and IL-6 are considered to be predictors of age-related sarcopenia 
(Kalyani et al., 2014; Wilson et al., 2017). We found that decreased lean mass 
was associated with an acute phase response (ESR, CRP). No association was 
found between the presence of low lean mass and prognostic factors (ACPA/RF 
positivity) or indices (DAS28, joint counts) that correlate with disease burden and 
the reduction of physical activity as a consequence. The finding suggests that BC 
could be improved by controlling inflammation. Of previous ERA studies, one 
found a weak association between low lean mass and disease activity (Book et 
al., 2009), but this finding was not replicated by other researchers (Dao et al., 2011; 
Turk et al., 2018). However, results regarding the effects of DMARD treatment 
on BC have been mixed. BC can be stabilized by achieving remission via tightly 
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controlled therapy, (Book et al., 2009), but the lean mass loss cannot be reversed, 
even with early treatment (Lemmey et al., 2016; S. M. Marcora et al., 2006). The 
only medication that has shown an ability to alter BC is an IL-6 inhibitor – an 
increase in lean mass was observed after one year of treatment with tocilizumab, 
possibly through the regulation of leptin that conventional DMARDs and anti-
TNF agents are not capable of mediating (Tournadre et al., 2017). An additional 
possible explanation for the lack of treatment effects is that the change in BC occurs 
very early in the course of RA, probably in the preclinical phase, and is resistant 
to alteration without specific pro-anabolic interventions (Lemmey et al., 2016). 
While DMARD treatment can potentially stabilize BC alteration, the long-term 
effects of GCS, another commonly used medication in RA, which leads to muscle 
wasting, fat accumulation, and fat redistribution, is a well-known phenomenon 
(Buttgereit & Burmester, 2016; Cutolo et al., 2014). We found short-term GCS 
usage (mean dose of prednisolone 13.8 mg, mean time from diagnosis 37 days) to 
be associated with 3.7 times higher odds of having low lean mass among the ERA 
subjects. The duration of DMARD therapy was too short to have a direct effect 
on BC. The limited data on the short-term effects of GCS use on BC parameters 
shows mixed results. Glucocorticoid therapy can have a double-edged impact on 
muscle mass – a positive effect resulting from the rapid reduction of inflammation, 
and a negative one by inducing protein breakdown and decreasing synthesis 
(Buttgereit & Burmester, 2016). Looking into previously published data, Dao et 
al. did not find GCS usage to be associated with a change in BC in early RA (Dao 
et al., 2011). The results of the COBRA study (a comparison of intense remission 
aiming treatment strategies in ERA) show an increase in FM without lean mass 
reduction in patients treated with high-dose, step-down GCS regimens after 26 
weeks (Konijn et al., 2016), indicating that a rapid decrease in inflammation 
counteracted the negative effects on BC. Inversely, a loss of lean mass was 
recently reported after a single high-dose intramuscular GCS injection (Lemmey 
et al., 2018).  
Data reported in ageing-related sarcopenia show that in addition to chronic 
inflammation, reduced physical activity and an inadequate diet are important 
contributors to the loss of lean mass (Beaudart et al., 2017; Cruz-Jentoft et al., 2019; 
Dent et al., 2018; Wilson et al., 2017). Protein supplementation is one of the 
options suggested for the treatment of sarcopenia (Beaudart et al., 2017; Dent et 
al., 2018; Geirsdottir et al., 2013). In the only study we found where the role of 
nutrition in RA induced muscle loss was assessed, no association was found 
between protein intake and sarcopenia in established RA (Barone et al., 2018). It 
has been suggested that diet and protein intake in patients with RA is not different 
from healthy controls (Challal et al., 2015; Rall & Roubenoff, 2004; Roubenoff, 
2009). Evaluating food intake using the 24-hour dietary recall, we found that 
early RA patients consumed fewer total calories and had lower fat and protein 
intake than control subjects. Low protein intake was associated with the presence 
of low lean mass (adjusted to age and gender). The 24HDR method provides 
detailed intake data but cannot account for day-to-day variability and is unable to 
assess long-term dietary exposure. There is no comparable data on the role of 
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nutrition in preventing of BC alterations, in RA but there is some evidence that 
dietary change may provide benefits in reducing disease activity (Chehade et al., 
2019; Cutolo & Nikiphorou, 2018; Petersson et al., 2018). The difference in 
nutrient intake between early RA and control subjects suggests that nutritional 
advice may have a valuable role in RA patient education, especially important to 
the patients with highest risk of lean mass loss – those on current glucocorticoid 
therapy. Further studies need to be performed to validate the potential benefits of 
nutrition and protein supplementation to prevent the loss of lean mass in RA. 
Sedentary lifestyle and immobility are established risk factors for sarcopenia 
in the elderly, and maintaining sufficient physical activity is the cornerstone for 
preventing of age-related muscle loss (Beaudart et al., 2017; Dent et al., 2018). It 
is well known that the majority of RA patients are physically inactive due to the 
movement limitations induced by arthralgia, stiffness, and active inflammation 
(Rall & Roubenoff, 2004; Sokka T. et al., 2008). High intensity resistance 
training has been shown to improve BC in RA, but is difficult to implement long-
term due to low adherence (Lemmey et al., 2009; Morsley et al., 2018; Rall & 
Roubenoff, 2004). Looking into previously published data, a lower frequency of 
regular intentional exercise has been observed in female sarcopenic early RA 
subjects in Vietnam (Dao et al., 2011). We found a notable gender difference in 
physical activity – women with ERA were more active than female controls, but 
the opposite was found in men, mirroring the higher disease activity observed in 
male subjects. After age and gender were adjusted for, we found the low ALM to 
be associated with low physical activity level among control subjects, but we did 
not find an association between physical activity and low lean mass in the ERA 
group. This finding, in light of the association between elevated inflammatory 
markers and low lean mass, emphasizes that hypermetabolism caused by inflam-
mation (Rall & Roubenoff, 2004) is more important in the loss of muscle tissue 
in RA than low physical activity: the main determinant of low lean mass among 
the general population. 
Finally, in accordance with results from previous studies in early and established 
RA (Book et al., 2009; Dao et al., 2011; Giles, Bartlett, et al., 2008; Giles, Ling, 
et al., 2008), we confirmed an association between low lean mass and disability – 
a 2.4 times increase in the odds of low lean mass was observed per every unit 
increase in the HAQ-DI score. 
 
 
9.2. Limitations 
Several limitations to our study should be acknowledged and taken into account 
when interpreting the findings. The modest sample size of the ERA group limited 
possibilities in statistical analysis. The difference in age and gender composition 
between RA subjects and population-based comparison group for papers II and 
III did not allow direct comparison between the groups, although age and gender 
adjustments were used in data analysis to limit bias.  
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The patients enrolled in our study were not treatment-naïve – 55% were on 
DMARD treatment and 29% received corticosteroids. The lack of pre-treatment 
data can also be considered a limitation. It is unlikely this had an impact on the 
BC measures or presence of cardiometabolic risk factors, but it may have 
interfered with the disease activity and inflammatory status assessment.  
The fact that there are no validated criteria for sarcopenia in RA complicates 
comparisons with previous reports. The current EWGSOP criteria are designed 
to be used with an elderly population (Cruz-Jentoft et al., 2019) and may under-
estimate the presence of sarcopenia in the general population and overestimate it 
in RA.  
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10. CONCLUSIONS 
1. Patients with early RA have an increased risk of metabolic obesity – a phe-
nomenon where metabolic syndrome develops at a normal weight status.  
2. Subjects with early RA have higher blood pressure than controls, but the 
proportion of rheumatoid patients receiving antihypertensive medication is 
lower, showing an underestimated need for treatment in this group.  
3. An important contributor to cardiovascular morbidity – insulin resistance is 
already present in a majority of RA patients in the early stage of the disease. 
Male gender and high inflammatory activity increase the risk of insulin 
resistance.  
4. The presence of insulin resistance cannot be predicted by body weight in 
RA, as reduced insulin sensitivity is associated with low lean mass.  
5. A change in body composition can be detected in the first months after the 
onset of synovitis in RA. Patients with early RA have a lower appendicular 
lean mass adjusted to body size and a higher body fat percentage compared 
to healthy controls. 
6. The presence of low lean mass in early RA is associated with higher inflam-
matory activity, glucocorticoid treatment, and lower protein intake, but not 
with age, physical activity, or smoking, as seen in control subjects. 
 
The findings of this study help to clarify the alterations in cardiometabolic risk 
profile in early RA. The results are important, as due to the potential of unrecog-
nized CVD in RA, a proactive approach in screening from the earliest phase of 
the disease is crucial for timely and appropriate intervention.  
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11. SUMMARY IN ESTONIAN 
Kardiometaboolsed riskitegurid ja keha koostise muutused  
varase reumatoidartriidi haigetel 
 
SISSEJUHATUS 
Reumatoidartriit (RA) on kõige sagedasem krooniline süsteemne põletikuline 
haigus levimusega 0,5–2%. RA korral kujuneb liigeskahjustus koos liigeseväliste 
nähtudega ja seejuures võib iseloomulik autoimmuunprotsess alata enne artriidi 
kliinilist avaldumist. 
Viimastel aastatel on RA ravis toimunud kiire areng, mis on suunatud võima-
likult varasele põletiku pärssimisele (Smolen & Aletaha, 2015), kuid vaatamata 
sellele ei ole RA patsientide elumus paranenud (Giles, 2019). RA-ga seonduv 
kõrgem suremus on tingitud peamiselt kardiovaskulaarsüsteemi haigustest, kuid 
lisarisk ei ole täielikult seletatav traditsiooniliste riskitegurite nagu rasvumine, 
diabeet, hüperkolesteroleemia jt esinemisega (Agca et al., 2017; Cutolo et al., 
2014; Giles, 2019). Südame-veresoonkonna haiguste esinemissageduse tõusu on 
kirjeldatud juba artriidi kliinilise avaldumise järel (Błyszczuk & Szekanecz, 
2020; England, Thiele, et al., 2018) ja aterogeense protsessi algus on võimalik 
juba prekliinilises staadiumis (Bartoloni et al., 2010).  
Rasvumine on üldrahvastikus üks olulisemaid südame-veresoonkonna haiguste 
riski tõstvaid tegureid. RA korral seostub rasvumine leebema haiguse kuluga ning 
väljakujunenud RA-ga rasvunud patsientidel on pigem madalam südame-vere-
soonkonna haiguste ja suremuse risk võrreldes normkaalulistega (England, Thiele, 
et al., 2018; George & Baker, 2016).  
Rasvumisega seotud kardiometaboolsete riskitegurite kogumit nimetatakse 
metaboolseks sündroomiks. Metaboolse sündroomi komponendid seonduvad 
koos esinedes kõrgema riskiga kardiovaskulaarhaiguse tekkeks kui igaüks neist 
eraldiseisvalt (R. H. Eckel et al., 2005). Kui üldrahvastikus on metaboolse sünd-
roomi esinemine seotud peamiselt adipoossusega, siis RA korral ei ole metabool-
sete riskitegurite esinemine kehakaalust sõltuv (Kerekes et al., 2014). Varasemad 
uuringud RA korral on näidanud, et väljakujunenud haigusega patsientidel on 
kõrgem metaboolse sündroomi esinemissagedus, kuid on ebaselge, millal need 
muutused kujunevad.  
Metaboolse sündroomiga seostub insuliinresistentsus (IR): insuliini ebapiisav 
toime glükoosi ainevahetuse regulatsioonis vähenenud vastuse tõttu perifeersetes 
kudedes. IR ei ole ainult glükoosi metabolismi häire, vaid ka oluline iseseisev 
ateroskleroosi ja kardiovaskulaarhaiguse teket mõjutav tegur (Laakso, 2015). RA 
korral on IR esinemissagedus oluliselt kõrgem kui üldrahvastikus, seostudes enam 
kõrgema põletikulise aktiivsuse ja haiguse raskuse kui kehakaaluga (Nicolau et 
al., 2017).  
Lihasmassi, lihasjõu ja funktsionaalse võimekuse langus sarkopeenia on tüüpi-
line vananemisega kaasnev seisund. Samalaadseid muutusi kirjeldatakse ka 
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mitmete krooniliste haiguste sh reumatoidartriidi korral. Vananemisega seotud 
lihaskao põhjuseks peetakse muutusi toitumises, vähenenud kehalist aktiivsust ja 
kroonilist madala aktiivsusega põletikku (Beaudart et al., 2017; Cruz-Jentoft et 
al., 2010). Sarkopeenia tagajärjeks on elukvaliteedi langus, kukkumised, osteo-
poroos, düslipideemia ja metaboolne sündroom, mis omakorda suurendavad 
südame-veresoonkonna haiguste riski ja suremust (Cruz-Jentoft et al., 2010; 
Marzetti et al., 2017).  
Kui lihasmassi vähesusele kaasneb liigne rasvkude, nimetatakse seda sarko-
peeniliseks rasvumiseks: rasv ladestub vistseraalselt ja infiltreerib skeletilihaseid. 
Selline seisund seostub sügavama insuliinitundlikkuse häire, madalama funktsio-
naalse võimekuse, elukvaliteedi ja elumusega kui rasvumine ja sarkopeenia eraldi 
(Cruz-Jentoft et al., 2019).  
Väljakujunenud haigusega RA patsientidest on sarkopeenilist rasvumist ilma 
kehamassi muutuseta kirjeldatud kuni 2/3 juhtudest (Challal et al., 2015; Summers 
et al., 2010) ja see võib olla üheks põhjuseks, miks normkaalulistel RA patsientidel 
on täheldatav kõrgem suremusrisk võrreldes rasvunutega (England, Thiele, et al., 
2018). 
Lihasmassi kadu RA korral on seotud sarkoaktiivsete põletikumediaatorite 
üleproduktsiooniga; oma roll võib olla ravimitel ja vähesel liikumisel (Tournadre 
et al., 2018). Keha koostise muutuse algus RA korral ei ole päris selge. Mõned 
autorid on avaldanud arvamust, et muutused kujunevad juba prekliinilises faasis 
(Giles, 2019). Uuringud Rootsis, Vietnamis ja Hollandis (Book et al., 2009; Dao 
et al., 2011; Turk et al., 2018) on kinnitanud, et varase artriidiga patsientidel on 
oluliselt madalam lihasmass võrreldes üldrahvastikuga. Andmed selle kohta, 
millised tegurid on muutuse tekkega seotud, on vastukäivad, peamiselt on hinnatud 
haigusega seotud tegurite (artriidi aktiivsus, ravi, prognostilised faktorid) mõju 
ilma, et oleks arvestatud eluviisi rolli.  
 
 
UURINGU EESMÄRGID 
Üldiseks eesmärgiks oli hinnata kardiometaboolset riski mõjutavaid tegureid 
varase RA korral. Töö oli suunatud keha koostise muutuste hindamisele ning 
seostele metaboolsete faktoritega varase RA patsientidel võrreldes üldrahvas-
tikuga. 
 
Töö eesmärgid: 
1. Hinnata kardiometaboolse riski profiili varase RA korral metaboolse sünd-
roomi, selle komponentide (artikkel I) ja insuliinresistentsuse (artikkel II) 
esinemise kaudu. 
2. Selgitada insuliinresistentsuse kujunemisega seotud tegureid varase RA 
haigetel (artikkel II) 
3.  Võrrelda keha koostist varase RA korral ja tervetel inimestel (artikkel III) 
4. Uurida seoseid keha koostise ning haigusega seotud tegurite, kehalise aktiiv-
suse ja toitumise vahel RA algfaasis (artikkel III) 
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UURITAVAD JA MEETODID 
 
Uuritavad 
Varase RA haigete grupis osales 92 järjestikust Tartu Ülikooli Kliinikumis 
reumatoloogi vastuvõtule pöördunud RA diagnoosiga patsienti, kelle puhul olid 
täidetud ACR/EULAR 2012. a reumatoidartriidi klassifikatsiooni kriteeriumid 
(Aletaha et al., 2010) ja vaevused ei olnud kestnud üle ühe aasta.  
Artiklis I kasutasime võrdlusgrupina 273 vanusele (+/– 3a) ja soole sobitatud 
uuritavat suhtes 3 kontrolli 1 RA patsiendi kohta, kes olid juhuslikult valitud 
2008–2009 a kolmes Eesti maakonnas läbi viidud rahvastikupõhises uuringus 
osalenute seast. 
Rahvastikupõhisesse kontrollgruppi (artiklid II ja III) oli kaasatud juhuvalim 
perearsti nimistust (332 uuritavat), kelle vanuseline ja sooline jaotus vastas Eesti 
rahvastiku 2013. a hinnatud struktuurile.  
 
Meetodid 
RA gruppi kuuluvaid uuritavaid küsitleti esmaste haigusnähtude tekke kohta, 
hinnati kaasuvate haiguste olemasolu ja ravimite kasutamist. RA diagnoos kinni-
tati elektroonilise haigusloo andmete põhjal ja uuritavad klassifitseeriti ACR/ 
EULAR 2012 kriteeriumide alusel.  
Füüsilisel läbivaatusel fikseeriti RA patsientidel turses ja valulike liigeste arv, 
kõigil uuritavatel mõõdeti kehakaal, pikkus, vöö ümbermõõt ja vererõhk. Artriidi 
aktiivsus määratleti DAS28 skoori abil.  
RA patsientide elukvaliteeti hinnati tervisehinnangu küsimustiku (HAQ-DI) 
alusel. Kehalise aktiivsuse tase määratleti vastavalt WHO soovitustele kasutatdes 
rahvusvahelise füüsilise aktiivsuse küsimustiku (IPAQ) andmeid. 
Patsienti küsitleti viimase ööpäeva jooksul tarvitud toidu ja joogi kohta 24 tunni 
toiduintervjuu meetodil. Andmed sisestati Tervise Arengu Instituudi poolt välja 
töötatud NutriData programmi, hinnati energiasisaldust ja toitainete kogust tarbitud 
toidus. 
Paastuplasmas määrati veresuhkru, ESR, CRV, kolesterooli, HDL ja triglütse-
riidide väärtused ning RA autoantikehade (RF ja antiCCP) olemasolu. Vereseeru-
mis mõõdeti IL-6, TNF-alfa ja insuliini tase. 
 
Metaboolne sündroom defineeriti NCEP ATP III kriteeriumide alusel, norm-
kaalulised metaboolse sündroomiga patsiendid klassifitseeriti metaboolselt 
rasvunutena. Rahvastikupõhise kontrollgrupi homeostaasimudeli (HOMA-IR) 
ülemise kvartiili alusel määrati insuliinresistentsuse olemasolu.  
Kehamassiindeksi alusel jagati uuritavad normkaalulisteks, ülekaalulisteks ja 
rasvunuteks. Kvantitatiivseks lihas- ja rasvkoe massi hindamiseks kasutati 
DEXA meetodil saadud tulemusi ja arvutuslikke indekseid. Lihasmassi hinnati 
jäsemete lihaskoe massi põhjal, rasvkoe massi keha kogu rasvamassi ja rasva-
protsendi alusel, piirväärtused määrati kontrollgrupi andmete põhjal. 
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TULEMUSED JA JÄRELDUSED 
1.  Varase reumatoidartriidi haigete ning vanusele ja soole vastava kontrollgrupi 
vahel ei olnud erinevust kehamassi indeksis ega metaboolse sündroomi esine-
mises (35,2% RA vs 34,1% kontrollgrupis). Reumatoidartriidiga patsientidel 
esines 5,6 korda enam metaboolset rasvumist – seisundit, kus metaboolne 
sündroom kujuneb normkaalu juures. Metaboolne sündroom esines 16,7% 
normkaalulistest varase RA grupis ja 2,3% kontrollgrupi samas kaalurühmas.  
2. Varase RA-ga patsientidel olid kõrgemad nii süstoolse kui ka diastoolse vere-
rõhu väärtused. Hüpertensioon esines 72,5% RA patsientidest ja 61% kontroll-
rühmas. Alahinnatud ravivajadust RA patsientidel näitas oluliselt väiksem 
kõrgvererõhktõve ravi saavate RA patsientide osakaal (31%) võrreldes kontroll-
grupiga (53%). 
3.  Insuliinresistentsus kui oluline kardiovaskulaarriskiga seonduv tegur esines 
suuremal osal RA patsientidest juba varases haiguse staadiumis. Keskmine 
insuliini tase oli RA korral oluliselt kõrgem kui kontrollgrupis. IR tõenäosus 
varase RA patsientidel oli 4,8 korda kõrgem kui kontrollgrupis.  
4.  Leidsime, et RA korral kehakaal ei ennusta insuliinresistentsuse olemasolu. 
RA grupis oli insuliinresistentsuse võimalus 7,4 korda kõrgem meessoost 
patsientidel võrreldes naistega; 6,2 korda kõrgem haiguse aktiivsuse korral 
võrreldes madala haiguse aktiivsusega patsientidega ja insuliinresistentsuse 
tõenäosus suurenes lihasmassi vähenedes.  
5.  Keha koostise muutus oli täheldatav juba RA kliinilise avaldumise esimestel 
kuudel. Varase RA patsientidel oli madalam jäsemete lihasmass keha pindala 
kohta ja kõrgem rasvkoe osakaal võrreldes kontrollgrupiga. Lihasmass oli 
madal 42% varase RA patsientidest (kontrollgrupis 20%) ja kõrge rasvkoe 
hulk 68% patsientidest (47% kontrollidest). Igal neljandal varase RA haigel 
(26%) leiti samaaegselt nii madal lihasmass kui ka liigne rasvkude (7% 
kontrollgrupis). Vanusele ja soole kohandades oli varasesse RA gruppi kuulu-
vatel patsientidel 3,3 korda kõrgem võimalus madala lihasmassi esinemiseks, 
1,9 korda kõrgem võimalus liigse rasvkoe esinemiseks ja 4,4 korda kõrgem 
tõenäosus samaaegseks liigse rasvkoe ja madala lihasmassi esinemiseks. 
6.  Leidsime, et madala lihasmassiga seotud tegurid varase RA patsientidel ja 
kontrollgupis olid erinevad. Suurema šansiga madala lihasmassi esinemiseks 
(kohandatuna vanusele ja soole) olid RA grupis seotud kõrgem põletikuline 
aktiivsus, madalam ööpäevane valgu tarbimine toiduga, glükokortikosteroidide 
kasutamine ja madalam elukvaliteet. Kontrollgrupis oli madala lihasmassi esi-
nemine seotud kõrgema vanuse, madala füüsilise aktiivsuse ja suitsetamisega. 
 
Uurimus näitas varase RA korral esinevaid kehakaaluga mitte seotud eripärasid 
kardiometaboolse riskiprofiilis. Metaboolsed häired nagu insuliinresistentsus, 
metaboolne sündroom, keha lihaskoe ja rasvkomponendi muutused normaalse 
kehakaalu juures on iseloomulikud alates haiguse algusest. Tulemused on 
olulised RA haigete südame-veresoonkonna kahjustuse riskiprofiili hindamisel ja 
mõjutamisel adekvaatse ja õigeaegse raviga. 
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